Developing a Multiplexing Assay System for the Quality Control of Cell Therapy Products by Vairagade, Amishi et al.
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
April 2017
Developing a Multiplexing Assay System for the
Quality Control of Cell Therapy Products
Amishi Vairagade
Worcester Polytechnic Institute
Julia Michelle Smith
Worcester Polytechnic Institute
Thai Thanh Trinh
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Vairagade, A., Smith, J. M., & Trinh, T. T. (2017). Developing a Multiplexing Assay System for the Quality Control of Cell Therapy Products.
Retrieved from https://digitalcommons.wpi.edu/mqp-all/4125
1 
 
Developing a Multiplexing Assay System 
for the Quality Control of Cell Therapy 
Products 
 
 
A Major Qualifying Project Report: 
 
Submitted to the Faculty of the Worcester Polytechnic Institute 
 
In partial fulfillment of the requirements of the Degree of Bachelor of Science 
 
By: 
 
 
Julia Smith 
 
 
Thai Trinh 
 
 
Amishi Vairagade 
 
 
April 27, 2017 
 
 
 
Prof. Kristen Billiar, Ph.D., WPI 
 
 
Prof. Edward Clancy, WPI 
 
 
 
 
This report represents the work of WPI undergraduate students submitted to the faculty as evidence of completion of a degree 
requirement. WPI routinely publishes these reports on its website without editorial or peer review. For more information about 
the projects program at WPI, please see http://www.wpi.edu/academics/ugradstudies/project-learning.html. 
 
2 
 
Abstract 
When used for autologous transplant, mesenchymal stem cells require extensive quality control 
(QC) before being reintroduced into the body. One standard method of QC is biological assays, which 
are a manually completed laboratory test for determining the concentration of foreign substances in a 
cell culture solution. Biological assays have a number of limitations including time, cost, and level of 
manual involvement. With these limitations in mind, a proof-of-concept device was developed to show 
the potential for an automated multiplexed assay device for QC. This prototype device design can 
accurately intake and dispense reagent volumes necessary for the completion of two assays, in a range 
between 50 and 350 µL. The device is also capable of providing the required temperature environment 
for each step of the assay process, changing between room temperature (24 °C) and 65 °C in under five 
minutes. 
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1 Introduction  
With current medical treatments, it is often difficult to target the source as well as the 
symptoms of chronic diseases, which are due to malfunctioning or aging cells. This results in inefficient 
and high cost medical treatment for patients. One possible solution is regenerative medicine.  This area 
of medicine focuses on treating the fundamental causes of the diseases rather than only the symptoms. 
Specifically, regenerative medicine aims to improve, repair, or regenerate damaged tissues by replacing 
them with healthy tissues or cells (Alliance for Regenerative Medicine, 2013). For example, when 
diagnosed with Type 1 Diabetes Mellitus, a patient is most often treated by continuously introducing 
insulin to body due to the malfunctioning of the pancreas. However, using regenerative medicine 
strategies, scientists are researching how to recover pancreatic cells and return them to a healthy, 
insulin-producing condition. The patient’s body can then naturally produce insulin without life-long 
treatment (United State Government Accountability Office, 2015).  
Currently, there are many important regenerative medicine technologies used in the healthcare 
industry, including cell-based therapy, gene therapy, and tissue engineering. Among these technologies, 
cell-based therapy is the most prominent, as it is currently involved in more than 1,900 clinical trials 
worldwide (Alliance for Regenerative Medicine, 2013). Cell-based therapy is a subsection of 
regenerative medicine that involves harvesting stem cells and progenitor cells such as mesenchymal 
stem cells or neural stem cells. This therapy also includes isolating differentiated adult cells from human 
body such as fibroblasts, osteoblasts, and myocytes. These healthy cells are then introduced into a 
patient’s body in order to replace non-functioning and damaged cells (Alliance for Regenerative 
Medicine, 2014).   
Cell-based therapy is a promising area in the medical field and can be used to treat many 
conditions and diseases, such as heart failure, cancer, and spinal cord injuries. Cell-based technologies 
have contributed to the treatment of more than 160,000 patients. From 2008 to 2013, 12 cell therapy 
products have received approval by various regulatory agencies (Alliance for Regenerative Medicine, 
2013). Some cell therapy products that have been approved by the U.S. Food & Drug Administration 
(FDA) are Fibroblasts from Fibrocell Technologies, Inc. and Clevecord, which is HPC (Hematopoietic 
Progenitor Cell) Cord Blood from the Cleveland Cord Blood Center (U.S. Food & Drug Administration, 
2017).  
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These cell-based technologies usually use three major types of cells: autologous, allogeneic, and 
pluripotent cells (National Cell Manufacturing Consortium, 2016). Autologous cells are the patient’s own 
cells, which are used as a personalized treatment. These can be used to recover the patient’s ability to 
produce blood cells after chemotherapy in order to help treat blood cancers such as leukemia and 
myeloma. Moreover, using the patient’s own cells reduces the risk of cellular incompatibility and graft 
vs. host conditions. Allogeneic cells are stem cells that harvested from a compatible donor. These cells 
can also help the patient to recover blood cell production after chemotherapy but has a high risk for 
immune rejection (Cancer Treatment Centers of America, 2017). Pluripotent cells can differentiate 
themselves into any of three basic body layer cell groups: ectoderm, endoderm, and mesoderm. As a 
result, pluripotent stem cell can produce any cell or tissue, which is useful for cell replacement for 
damaged organs or tissues (Boston Children’s Hospital, 2017).   
Though cell manufacturing has the potential to greatly benefit patients, the cells used in the cell-
based products require intense maintenance and quality control to ensure their viability and safety. It is 
very crucial to ensure that the cells injected into the patient’s body are safe and uncontaminated. 
Current methods of stem cell quality control include models, assays, and sensors to gauge the quality of 
the cells. These methods can be not only be expensive but also time consuming. There are other 
challenges associated with the current quality control methods such as difficulty with obtaining 
reproducibly accurate results, which can lead to potentially harmful errors. Inaccurate results not only 
compromise the quality of the cells but can also be dangerous and even life threatening for the patient 
(National Cell Manufacturing Consortium, 2016).  
The purpose of our project is to overcome these quality control challenges by designing and 
creating a proof-of-concept device to demonstrate the ability of multiplexing assays used for testing 
mesenchymal stem cells (MSCs), which will be used for autologous transplant.  The current quality 
control of MSCs has several challenges associated with it. The current quality control tests using assays 
are performed manually by a laboratory technician and involve steps such as pipetting, transferring, and 
incubating. Because of the cost of the off-the-shelf assay kits as well as the manual labor involved in 
these tests, the cost of quality control is very high and one of the most expensive aspects of the cell 
therapy process. Furthermore, running these assays can be time consuming as each assay can take up to 
seven hours to complete, resulting in higher labor costs and extensive time spent on this area.  Another 
limitation of running these assays manually is that it may result in human errors like reproducibility, 
false negatives and false positives. False negatives are particularly dangerous because if contaminated 
cells are reintroduced into the body, severe side effects can take place for the patient and health could 
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be compromised. False positives can result in viable cells being discarded leading to a waste of cells, 
time, and cost associated with the tests. Thus, it is important to build and design a device that can 
multiplex these assays while reducing the costs involved in the quality control and reducing the time 
involved in running these tests. 
For this project, our MQP team created a proof-of-concept device to show the potential for an 
automated, multiplexing assay device that our client, Triple Ring Technologies, could further develop in 
the future. Because of the early stage of this project, the prototype was unable to reach all goals laid out 
due to time constraints but we see this device being capable of solving many of the aforementioned 
problems after future development and implementation. This device ideally would be able to 
simultaneously perform key quality control assays on a single patient’s MSC sample to ensure that the 
cells are healthy and viable before reintroduction into the body. The device would require little manual 
involvement and would consequently result in lower labor costs, reduced time spent on quality control, 
and higher reproducibility and accuracy. This product could eventually be a marketable device that can 
greatly assist with the quality control of cell therapy products.  
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2 Background  
2.1 Regenerative Medicine 
The medical field has advanced through the years and has seen innovation in treating various 
diseases. One such important advancement in the medical field is regenerative medicine. Regenerative 
medicines are used for the treatment of a part of the body that has damage due to a health condition or 
aging. Regenerative medicine is focused on treating the root of the health condition in order to address 
it. Though still a growing field with much room for improvement, regenerative medicine is an important 
innovation in the healthcare industry as it has led to effective health care treatment. Regenerative 
medicines include a wide spectrum of approaches involving cell-based therapies, gene therapy, biologics 
and small molecules, tissue engineering, stem cells, and biobanking to treat many serious conditions. 
(Alliance for Regenerative Medicine, 2013). 
Cell-based therapies are a subset of regenerative medicine in which healthy cells are used to 
heal the impaired part of the body. This method of treatment promotes and strengthens the body’s 
immune system by redeveloping and renewing the body’s cells. Cell based therapies usually use 
hematopoietic stem cells and mesenchymal stems cells which are undifferentiated adult stem cells. 
These cells differentiate to form other cell types such as intestinal cells, muscle cells, and blood cells. 
Because of the variety of cells that MSCs are able to differentiate into, they are very versatile and have 
almost unlimited potential for applications in a wide range of diseases (Bender, 2016) 
2.2 Stem Cells 
Stem cells are undifferentiated cells that are found throughout most tissues in the body. These 
cells are capable of differentiating into a large variety of different cell types depending on their location 
and the function of the surrounding tissues. Because of their renewable properties, stem cells can repair 
themselves and are often responsible for the repair of the surrounding tissue by differentiating into the 
appropriate type of cell, depending on the tissue’s needs. (NIH, 2016).   
2.2.1 Mesenchymal Stem Cells (MSCs) 
This project focuses on mesenchymal stem cells and their potential applications in research and 
the treatment of a variety of diseases. Mesenchymal stem cells are valuable because of their ability to 
differentiate into a large range of cell types. The applications for these cells and their potential to treat a 
variety of different diseases and disorders make them very valuable to the scientific research 
community. Some current applications research include the treatment of cardiovascular diseases, 
neurodegenerative disorders such as Parkinson’s and Alzheimer’s, and autoimmune diseases including 
rheumatoid arthritis and type 1 diabetes. However, these cells become less capable of differentiating 
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quickly with increasing cell culture passages, therefore all cells collected must be put to use because it is 
difficult to ensure a constant supply of viable cells. (Ullah, et al, 2015).   
The particular stem cells that are the focus of this project are mesenchymal stem cells (MSCs). 
These stem cells are derived from an adult human and were originally thought to be found only in bone 
marrow (NIH, 2016). However, more recently, scientists have shown that they are found in virtually 
every tissue in the body including adipose tissue, amniotic fluid, and even umbilical cords. Depending on 
their location, MSCs have the potential to differentiate into a range of other cell types, in particular, 
bone, cartilage, fat, and even occasionally neural cells (Ullah, et al, 2015).  Additionally, they can also 
differentiate into stromal cells which are assistive in the support of blood production (NIH, 2016). 
2.3 Applications of MSCs 
2.3.1 Therapeutic Applications 
Stem cell therapy is a relatively new area of medicine and its possible applications are seemingly 
limitless, though most areas of research have not been advanced past clinical trial stages of treatment. 
Research conducted in recent years has shown that cell therapy treatments can assist with healing of 
bone and cartilage diseases; this process required infusion of MSC rich bone marrow into the affected 
area to help combat both osteogenesis imperfecta and hypophosphatasia. This therapy can also be used 
to address various cardiovascular diseases which is highly beneficial given the non-regenerative nature 
of cardiovascular cells. Infusion of MSCs in the affected region can assist in recovering from heart 
disease, heart failure, and myocardial infarction. Autoimmune disease such as Crohn’s disease and 
Rheumatoid arthritis can also benefit from the anti-inflammatory properties of the MSCs. (Kim, Cho, 
2013).  
2.3.2 Autologous Transplant Therapy  
The application of MSCs for this project is in autologous MSC transplant therapy. Autologous 
transplant therapy is a method of cell therapy in which a patient’s own cells are harvested, preserved, 
and reinjected into the body after a period of time. This therapy is most often used as a treatment for 
blood conditions or cancers like lymphoma or leukemia. Because the chemotherapy required to treat 
these condition destroys cancer cells as well as blood forming cells found in bone marrow, it is helpful to 
resupply the body with healthy and unaffected stem cells to quicken the time it takes for the body to 
regenerate the lost blood cells.  
The process for autologous transplant consists of multiple steps: harvesting, preservation, 
quality control, and reinjection into the body. MSCs are collected from the bone marrow when the 
patient is relatively healthy or just prior to chemotherapy or radiation treatment (Leukemia & 
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Lymphoma Society, 2017). Stem cells are typically collected using apheresis, where they are isolated 
from the bone marrow. The collected stem cells are then either cryogenically preserved until needed or 
cultured to expand the number of cells available and then cryogenically preserved until required. If the 
stem cells are cultured, they must undergo extensive quality control to ensure purity before 
reintroduction to the body. 
Once the cells are required, generally after cancer treatment has been completed, the stem cells 
are reinfused into the body, typically through a central venous catheter. Once the cells have been 
reintroduced, there is a period of time necessary for the engraftment of the saved cells in which they 
are required to replace all cells that had died during treatment. After this period of time has passed, the 
cells are able to regrow and regenerate as required. (Memorial Sloan Kettering Cancer Center, 2017).  
2.4 MSC Quality Control for Autologous Transplant 
In the biotechnology field, when biomedical products such as MSCs are to be used in human or 
animal therapeutics, they need to be appropriately purified from contaminants to prevent health risks. 
Contamination in the final product can come from outside sources or excess amounts of residual 
substances used during the cell culture process. Therefore, it is important to ensure that the 
concentration of residual substances or contaminants in the final product are within FDA approved 
limits. Biological assays are one method used to identify presence of specific contaminants in a cell 
solution.  
2.4.1 Toxin Detection Assays  
During the cell culture process, it is possible for the cultures to be contaminated by certain 
toxins, such as bacteria. These toxins can be very harmful and can fully compromise the culture and all 
cells being grown because of the potentially harmful effects they could have on the cells and on the 
patient who would be receiving the cells. Therefore, it is very important that the MSCs used for 
autologous transplant are rigorously tested for these toxins to ensure maximum safety for the patient.  
2.4.1.1 Toxin Detection Assays: Mycoplasma  
One of the most common biological contaminants is mycoplasma. Mycoplasma is a 
microorganism that has the capacity to modify certain properties of the cell it infects, including its 
development patterns. It is also capable of inducing the spread of viruses and yield in the infected cell 
culture. (Ryan, 2008).  
Mycoplasma is a dangerous contaminant because its microscopic size allows it to easily infect 
cultures and remain potentially undetected. Additionally, these small microorganisms have the ability to 
replicate themselves and, because they lack cell walls, can quickly reproduce and infect the cell culture. 
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Mycoplasma colonies are hearty and difficult to destroy which enables them to grow rapidly in a healthy 
cell culture environment. Because of these characteristics and the potential for health risks for patients, 
it is very important that cells be tested for mycoplasma before they are reintroduced into the body. 
(Ryan, 2008). 
2.4.1.2 Toxin Detection Assays: Endotoxin 
Another toxin that is important to test MSCs for is endotoxin. Endotoxin is a complex 
lipopolysaccharide found in gram negative bacteria and is released upon both cell death and 
reproduction of the bacteria. Endotoxin infection can cause a number of problems in both in vitro and in 
vivo environments, making it very important to identify its presence as soon as possible. In an in vitro 
environment, endotoxin can cause a multitude of problems with cell cultures as it affects production of 
macrophages and can inhibit colony formation of the desired cell type. In vivo, endotoxin infection can 
result in inflammatory and pyrogenic responses, beginning with fever and chills and sometimes 
worsening to potentially fatal septic shock. (Sigma Aldrich, 2017). Endotoxin is carried on laboratory 
equipment because of its affinity for hydrophobic surfaces such as cell culture plates. This toxin is 
particularly problematic because of its high stability and resistance to heat, which makes it difficult to 
eradicate using normal sterilization methods, particularly autoclaving. (Sigma Aldrich, 2017).  
2.4.2 Residual Cell Culture Material Assays   
In order to ensure the purity of the cells, it is important to test for residual cell culture materials. 
Some cell cultures may involve use of residual cell culture material derived from animal sources, 
particularly bovine or porcine. These may cause contamination of the cells with adventitious agents. 
Thus, it is important to test for residual cell culture materials to confirm the viability and purity of the 
cells. (Bioreliance, 2017).  
2.4.2.1 Residual Cell Culture Material Assays: Bovine Serum Albumin (BSA) 
One such substance cell culture is tested for is Bovine Serum Albumin (BSA). Serum is an 
important part in tissue engineering and cell culture as it is used to supply nourishment to the culture. It 
also acts as a carrier for essential compounds like hormones, growth factors, and nutrients. (Francis, 
2010).  
It has been observed that BSA infusion can have ill-effects on health. It has been observed that 
albumin can result in increased capillary permeability, excessive circulation, and pulmonary edema. 
(Drummond & Ludlam, 1999). Additionally, it is important to be cautious with the use of any animal 
based products when culturing cells that will be reintroduced to the human body, as this can also have 
ill effects. In general, animal derived serums an lead to many problems with human MSC culture 
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including introducing variability in the culture, changing cell growth patterns, and contaminating the 
culture with cytotoxic factors found in the serum. It can also be a risk for introducing viruses, bacteria, 
prions, bacteria, and other contaminants into the cell solutions. These contaminants can compromise 
the health of the cells and the patient if the cells are reintroduced into the blood stream. Finally, the use 
of animal based serum can disrupt the adhesion of the cells and cause hindrance of the cell growth. This 
disruption may result in disturbing the stability of the cells and further interfere cell growth and function 
(Tekkatte, et al., 2011). 
2.4.2.2 Residual Cell Culture Material Assays: Trypsin  
Trypsin is a material that is formed in the pancreas and is very commonly used in adherent cell 
culture (Sigma Aldrich, 2017). Its main purpose is to cleave peptides on lysine and arginine side chains 
which effectively breaks the bonds between adherent cells and the cell culture plate in which they grew 
(Worthington Biochemical Corporation, 2017).  
Trypsin is typically taken from either bovine or porcine sources when used in cell culture. This is 
an important material to test for as residual material because of its non-human source. It is risk-inducing 
to reintroduce cells into the body that have been exposed to an animal based material. Trypsin can carry 
viruses that are prevalent and difficult to eradicate in the porcine population. It can additionally be 
contaminated with other adventitious agents that can cause changes in cell cultures and difficulties with 
creating a suitable biological product. (European Medicines Agency, 2014).  
2.4.3 Limitations of Quality Control  
Biological assays are some of the most popular laboratory methods for detecting potentially 
hazardous substances in cell solutions. They are used in hospitals, laboratories, industry and research to 
identify the presence and concentration of particular substances in a cell solution including proteins, 
antibodies, and hormones. These tests perform based on the principles of the binding ability of 
antibodies, which are proteins generated by the immune system in response to the presence of foreign 
agents like bacteria. Due to their high specificity to bind to certain molecular structures, antibodies are 
used in some assays to detect certain biological molecules. (ImmunoChemistry Technologies, 2017).  
However, these assays have significant room for improvement. The main concerns with these assays are 
the high cost, time commitment, and possibility for human error involved.  
Off-the-shelf (OTS) assay kits are expensive and vary greatly in cost range. For example, the R&D 
Systems' Proteome Profiler Human Kidney Biomarker Array price per kit is $495, which breaks down to 
$125 per sample and $3.28 for each data point. R&D Systems' Fluorokine® MAP Multiplex Human 
Inflammation 12-plex kit costs $2,390, which breaks down to $30 per sample and $2.5 for each data 
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point (Biocompare, 2011). In addition to these examples, there are hundreds of other assay kits on the 
market with costs that range from hundreds to thousands of dollars. These OTS assay kits are also very 
time consuming to perform. For example, the MycoProbe® Mycoplasma Detection Kit from R&D 
Systems requires five hours to run the whole assay (R&D Systems, 2016), not including sample and 
reagent preparation time. Another example is the MyBioSource BSA Detection Assay kit, which takes up 
to two hours to complete, with additional time again required for preparation (MyBioSource, 2016). 
Finally, a considerable amount of manual work is involved in executing assays, which involves manual 
procedures like pipetting, washing, and transferring of solutions. Moreover, running the assay 
procedures manually may introduce risk for human error and difficulties in reproducibility. An 
experienced operator is required to ensure that the assays are correctly executed. It is crucial to ensure 
the assay procedure is performed correctly since the therapeutic applications rely on the stable and 
accurate data.  
With consideration of the above limitations, an automated system to perform all the 
aforementioned assay procedures would be extremely beneficial to help reduce expenses and increase 
confidence in results. This device could be used to execute assays by utilizing automated fluid and 
temperature control, reducing manual involvement. Additionally, more accurate and consistent results 
could be accomplished by testing the repeatability of such a device. Furthermore, the device can 
decrease costs related to instruments required to run the assay. Finally, by scaling reactions to use 
smaller volumes of reagents can be used to further reduce the costs involved in QC.  
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3 Project Strategy  
3.1 Initial Client Statement  
The client for this project was Triple Ring Technologies (TRT), a research and development firm 
that specializes in medical devices, in vitro diagnostics, and imaging. TRT created this project as a 
continuation of previous work done within the In Vitro Technologies department. The original client 
statement for this MQP is as follows.  
“The goal of this project is to develop a concept and prototype device that demonstrates 
multiplexed assays used in the quality control (QC) testing of stem cells manufactured for autologous 
transplant. Because these QC tests are currently performed manually with separate technologies, they 
are one of the more expensive components of the stem cell manufacturing process. We would like to 
significantly reduce the cost of QC by developing a system that bundles a number of tests into a 
compact, automated cartridge.” 
Using this client description, the project team was able to initiate background research to 
become familiar with the field of quality control testing and potential solutions to the problem at hand. 
3.2 Design Requirements 
3.2.1 Objectives     
At the project outset, TRT provided a number of design requirements for the device. These 
objectives were necessary to guide the group through the brainstorming and design process to ensure 
that the eventual prototype addressed the client’s needs for the product. Though this project is one that 
will be continued after the completion of our work, our group worked to incorporate as many of the 
constraints and specifications as possible so that the continuing work would proceed toward final 
product success.  
The assay instrument or device should be capable of multiplexing assays simultaneously in one 
device. The design and system architecture of the device should consider proper temperature control 
for incubation areas and time. It should also consider reagent mixing and fluid motion to ensure all 
assays run in the device are completed correctly and without contamination with each other. The 
instrument should possess proper fluidics control and be able to manage temperatures within the 
device. For this project, a proof-of-concept prototype device should be created to show that this 
potential design could be possible in the future. 
The pretotype portion of the project should be a product concept of the product as it could be 
far in the future. This pretotype should have all objectives met by the device in order to show how the 
product could be a useful and necessary addition in labs. Additionally, it can include drawings in order to 
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illustrate product concept and workflow or potentially 3D mockups of the system. Therefore, potential 
clients and buyers can better visualize and see the need for this product and realize its future 
advantages over the gold standard QC methods on the market now. 
3.2.2 Engineering Standards  
During the engineering design process, it is vital to consider the industry and engineering 
standards that are relevant to the system at hand. Because this system is meant to prove that cells are 
useable in the human body, there are strict guidelines that it must conform to in order to be considered 
safe and effective. For this project, it was necessary to look at standards regarding sterility, testing, 
electrical limitations as well as other areas. The group did research to determine the standards in these 
areas according to ISO standards, FDA requirements, ASTM standards, and IEC standards. 
One of the standards used to ensure the quality and the safety of the device is ISO (International 
Organization for Standardization) 11737-2:2009- Sterilization of medical devices. This standard states 
important testing required to avoid any contaminants on the medical device thus ensuring patients’ 
safety (ISO 11737, 2009).  
IEC 60601-1 is a standard covering electrical equipment for medical use. This standard regulates 
safety requirements for electrical connections like plug insulation and flexibility of power cords. 
Moreover, there is a subsection describing constraints for medical electrical equipment including risk 
management, testing methods, and classification. With this standard, we have a guideline for how to 
prevent potential harm like electrical shock to users (IEC 60601-1, 2015).  
IEC 60083 provides information about plugs system and socket-outlets in several countries 
around the world. For example, it gives information about pole numbers, shape, alignment, voltage and 
current for sockets in Australia, Austria, and other countries. Knowing this data, it is helpful for us to 
specify the compatibility of our product’s power usage with the power system in different countries.  
IEC 60252-1 provides information about safety requirements for AC motor capacitors, which 
includes performance, testing and rating. Some details can be mentioned are the phase system, 
frequency specifications and capacitor types. Since our project involves pumping, which may result in 
usage of motors, it is important to consider these constraint to the product so as to prevent possible 
damage (IEC 60252, 2010).  
ISO 9001: International Organization for Standardization (ISO) specifies ISO 9001:2015, which 
incorporates/includes quality management system in any field in over 170 countries. This standard helps 
in customer satisfaction by ensuring the quality of the products (ISO 9000, 2017).  
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ISO 13485: It is very essential to bind to medical device standards in order to ensure safety of 
the patients. Another very important standard is ISO 13485, which ensures the quality management of 
the system. This standard is applicable for organizations which are involved in design, 
manufacturing/production, distribution, installation or servicing of medical devices or anything similar 
or related (ISO 13485, 2016).  
ISO 14001: 2015 is an environment management ISO standard. The standard identifies the impact 
of the medical device on the environment. It recognizes the effects of manufacturing the device and its 
parts on the environment. This helps ensure a safety environment for the company and its employees as 
well (ISO 14000, 2015).  
3.3 Revised Client Statement  
During the initial research period, our MQP team was able narrow our project focus by working 
with TRT to ensure that client needs would be met by our design. The revised client statement below 
was a result of this work.  
“The goal of this project is to develop a concept and prototype device that demonstrates semi-
automated fluidic and temperature control to show potential for a multiplexed assay device to be used 
in the quality control (QC) testing of mesenchymal stem cells (MSCs) manufactured for autologous 
transplant. The assays of concern in this project test for mycoplasma and bovine serum albumin 
(BSA).  We would like to significantly reduce the cost of QC by developing a system that bundles these 
tests into a compact, automated system with easy-to-read, absorbance based results. Additionally, this 
automated device would be required to meet the minimum requirements for FDA level sensitivities for 
the results of these performed assays.” 
3.4 Project Management Approach  
This project was a three term project conducted both on campus at WPI and onsite at the 
client’s facility in Newark, CA. It consisted of a preparation period (seven weeks prior to arrival), an 
implementation period (eight weeks onsite) and concluded with a completion and documentation 
period (seven weeks after the project duration). A number of methods were employed to ensure good 
planning and time management for the duration of the project.  
During the preparation term, the team worked to develop an understanding of the project 
background and be more prepared for the onsite portion of the project. The team had weekly meetings 
with our TRT project liaisons:  Director of In Vitro Technologies (Roger Tang), Practice Lead of In Vitro 
Technologies (Ryan McGuinness), and a Senior Scientist (Optical Technologies) and WPI alumnus (Jen 
Keating). These meetings were meant for the team to present progress and pose questions to our 
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liaisons for the coming week’s research.  Additionally, the TRT team provided a number of resources to 
expedite the process, including documentation of current research and the current state of the project. 
TRT also provided documents regarding the motivation behind the project, namely reports on 
regenerative medicine, the market potential for this field, and discussion on its future developments.   
In the future, it would be beneficial for the project to incorporate a Pre-Qualifying Project (PQP) 
official course registration in order to ensure that the students are prepared for the background 
research and preparation that needs to be completed before arriving onsite at the company. Because 
this project was the first of its kind, there was not a registered PQP and despite weekly meetings and 
information sharing with TRT liaisons, our group was unable to complete the required preparation work 
and research because of time limitations due to academic course load. Therefore, future MQP teams 
could benefit from a scheduled PQP to ensure that scheduling other academic courses can be balanced 
with the preparation work for the project.   
3.4.1 Gantt Chart  
 Upon arrival at TRT, the group worked to compile a Gantt chart with a potential outline of the 
term and the tasks that would be required to complete the project in a timely manner. This chart can be 
seen in Table 1 and Figure 1 below. 
Table 1 Project Gantt Chart Breakdown 
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Figure 1 Project Gantt Chart 
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3.4.2 Scrum Methodology: Daily Stand-up Meetings  
Per the suggestion of the TRT team, the team implemented a specific facet of agile development 
and scrum methodology, mainly the daily stand-up. Scrum methodology refers to the highly iterative 
process of discussing daily what was achieved the previous day, what the goals for that day are, and 
what is standing in the way of progress. The MQP team had a short daily meeting with the TRT team to 
discuss these daily goals and ensure that progress was being made as expected by addressing problems 
as soon as they arose. These meetings were helpful in more specifically breaking down tasks and 
creating the agenda for the day’s work. This type of organization was necessary because of the short 
nature of the onsite portion of the project and the need for maximum progress as fast as possible.  
3.4.3 Weekly Client Meetings  
A weekly meeting, with the TRT team, MQP team, and WPI advisors was also a tool to stay 
organized and on-track. This project was required to satisfy the WPI MQP requirements for the 
Biomedical Engineering and Electrical and Computer Engineering departments. Therefore the team had 
an academic advisor from each department to gauge progress of the project in both areas. These 
meetings were helpful in showing the progress the team had made over the last week while also 
allowing the opportunity for feedback and questions on the work done. 
3.4.4 Trello Board  
For additional organization, the team created a more detailed breakdown of tasks using an 
online project management tool called Trello. Trello facilitates digital implementation of agile 
development including the ability to add tasks with detailed checklists, assign tasks to individual team 
members, upload results, and conduct discussions through comments on tasks. 
The use of Trello allowed for easy parallelization of work through distribution of work to all 
team members. Tasks in Trello are easily modifiable and were actively modified to incorporate 
additional items needed to complete work. The tasks were organized and broken down roughly 
according to the part of the prototype system that was affected by the task: fluid control, temperature 
control, and assay experimentation and design. Once specific tasks were completed, they could be 
checked off and new tasks could be added so that progress could be made and monitored.  
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4 Design Process  
4.1 Needs Analysis  
4.1.1 Clinical/Patient Need 
Every year, almost 60,000 stem cell transplants are performed all over the world. These 
transplants are performed for treating disorders like cancer and blood related conditions (Alliance for 
Regenerative Medicine, 2013). According to the Alliance for Regenerative Medicine Annual Report 
(ARM), the cell therapy industry generated over $900 million for bio-therapeutic companies in 2012. The 
clinical need for this project revolves around the necessity for quality control for the transplanted cells. 
If this quality control process is ineffective, the patient’s health could be compromised, which remains 
the main concern and motivation behind these tests. Because these biological assays are currently 
performed by hand, human error can be introduced into the QC process, which can have dangerous side 
effects for the patient involved. For example, if because of human error a toxin detecting assay comes 
back with a false negative and the cells are wrongly assumed to be safe for reintroduction into the body, 
the patient’s health could be compromised. In the case of a toxin such as endotoxin, presence of the 
toxin in an in vivo environment can have serious consequences including fevers, chills, immune 
responses, and potentially fatal septic shock (Sigma Aldrich, 2017). Therefore it is crucial that these tests 
be performed reproducibly and without error. Additionally, in a more economic view, false positives can 
also present issues during QC. If false positives are present, the cells in question would need to be 
disposed of and would not be approved to be used as a therapy. However, if the contaminant in 
question was not actually present and the cells were healthy and uninfected, a significant amount of 
time and cost would be wasted and the patient would lose the opportunity to have the cells reinjected.  
These biological assays are also cost and time intensive. Assay kits can be expensive, with coast 
and amount of included reagents varying greatly from kit to kit. For example, the R&D Systems’ 
Proteome Profiler Human Kidney Biomarker Assay can cost $495 per kit, while the R&D Systems’ 
Fluorokine MAP Multiplex Human Inflammation 12-plex kit can cost $2390 per kit (Biocompare, 2011).  
The time involved is also high, as one of these assay runs typically takes a minimum of three hours of 
total time with intermittent manual involvement. Some OTS assays like the Mycoprobe Mycoplasma 
Detection Kit can take up to four and a half hours to complete with additional manual steps that can 
increase the total time (R&D Systems, 2016). In the case of autologous transplant, each round of QC 
would have to be performed separately because of the risk of cross-contamination between the cell 
types. Therefore, because each set of cells would have to be tested separately, the time cost involved in 
the process is problematic and greatly increases the cost of the process as a whole. The high cost of 
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these OTS kits coupled with the assay completion time and manual labor costs cause QC to be the most 
expensive part of autologous cell therapy process. If the time and cost involved with completing these 
assays was reduced using an automated, multiplexed system, research and QC laboratories could greatly 
increase throughput, lessen QC total cost, and have greater assurance of the accuracy and reliability of 
the test results.  
4.1.2 Client Need 
The client need for this project is motivated by the creation of a new TRT medical device that 
can be released to the market in the future. In the short term view, TRT looked at this project as the 
opportunity to progress the device enough ahead to apply for the California regenerative medicine grant 
to ensure that the research and testing necessary to develop this product could be funded for the 
foreseeable future. Our client hoped that our MQP team could accomplish a proof-of-concept device 
that would assist in applying for the grant and showing the potential of this product in the future. 
4.1.3 Device Requirements  
The requirements for this device were in a way rather non-specific because of the early stage of 
the project. Because our team was developing a prototype/proof-of-concept device, it was often 
necessary for the team to create logical specifications that were unspecified by the assay manufacturers 
or the TRT team.  
The first consideration was the necessity for a properly coated surface on which to run the 
assays inside the device. Because some assays, especially the ELISA (enzyme linked immunosorbent 
assay) category, require a modified surface that will allow for specific bindings to take place, it was 
necessary to the device to possess the correct type of plate for these reactions. Additionally, TRT’s goal 
was to have all result collection completed by an absorbance microplate reader, a standard machine in 
most biological labs, in order to simplify the device slightly. Therefore, it is necessary that whatever 
surface the assays are conducted on can be moved and fit into a standard reader for data collection. 
For the quality control biological assays to be able to be run correctly, the created device would 
be required to move the manufacturer specified volumes of each reagent around the device, as 
necessary. These volume specifications can be found in the OTS assay inserts and range from 50-350 µL. 
The exact volumes for each reagent vary depending on the kit being used, but in general this range of 
volumes would need to be accurately controlled by the system. There was no specific flow rate or time 
of output necessary for this subsystem of the device but the team wanted to be able to replicate the 
flow and time of the reagent through the system to closely resemble those of an actual lab pipette. 
Additionally, there could be no splashing or cross-contamination between the wells so the team would 
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also have to ensure that there was enough control over the fluid to limit these areas as much as 
possible.  
The assay kits also have a specified temperatures at which the reagent mixtures must incubate 
in order for the chemical reactions to be completed successfully. Most kits that our team researched did 
not have specific tolerances so the group decided that the temperature system should be able to heat to 
within 2-3 °C of the required temperature to reduce the possibility of error due to the temperature 
level. The team also had to decide on what length of time was acceptable for the heating system to have 
to heat up and cool down to the desired temperatures. These specifications were decided based on the 
incubation time and temperature required by the assay kits. For example, for a temperature of 65 °C 
that would incubate for one hour, the team decided that the system should take no more than five 
minutes to heat and cool to and from room temperature to ensure that solutions would be at the 
appropriate temperature for as close to the required time as possible.  
4.2 Alternative Designs  
 During the project design process, the group came up with a variety of different options and 
solutions to the problem at hand. Many possible components were considered before final decisions 
were made and used in the prototype. These options were either researched, discussed, and found to 
be ill-fitting for the design or were experimented with to determine their potential usefulness to the 
design. All of these options were considered and contributed to the design process in some way to 
ensure that the final design had the most appropriate and useful components. The main areas for which 
different options were considered were in regards to assay plates, fluid control, and temperature 
control. 
4.2.1 Ideal System Architecture  
During the brainstorming process, the team decided to create a long-term, end-goal 
architecture for the system to have a more definite idea of what components were necessary for the 
prototype. Though this architecture describes a number of subsystems that our team was not able to 
address, it provided an idea of how our prototype could develop more in the future and what areas 
would need to be implemented and improved. Figure 2 below shows the whole system architecture and 
lists the subsystems and components we deemed necessary to have a potentially successful final 
product.  
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Figure 2 Architecture Drawing of Ideal System Breakdown 
4.2.2 Assay Plate  
One option that the team considered for the assay plates needed to run these tests was to 
create a PDMS cartridge using a 3D printed negative mold to form fluidic channels. The assay reagents 
would be pumped through various parts of the cartridge and heated appropriately when required. 
However, one major flaw with this potential design was the necessity of duplicating the surface 
chemistry that is present in OTS kit assay plates. Since the assays of concern are ELISA based assays, they 
require a specifically coated surface on which the appropriate binding and reactions can take place. 
Because of the proprietary nature of the assay kits, these surfaces are very difficult to replicate. 
Attempting to do so would require an extensive amount of time to determine the correct substances 
while also experimenting to ensure that the correct bindings take place.  
To avoid recreating the surface chemistry on the assay plates, the team also looked at using the 
existing OTS assay plates to see how they could be integrated into a potential device. Using the 
preexisting plates would allow for correct binding and would remove one potential area for error in the 
device. The plates included in the kits were also stripwell plates which was another benefit because the 
assays typically only need 8-16 wells, or 1-2 strips of 8 wells, on which to run the assay. Therefore, the 
other wells would not have the potential of being contaminated because only the needed number could 
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be removed. Finally, these plates already fit a standard absorbance plate reader. This would eliminate 
the need for creating a cartridge that had the proper dimensions to fit in the reader correctly.  
4.2.3 Microcontroller 
Since the two main blocks of our project, temperature and fluid control, must be automated the 
heart of the whole system should be something that allows user to give instructions to the system 
through a friendly interface. Moreover, we also wanted to have data recorded from these systems to 
facilitate testing protocol. Lastly, the control system should be small enough to fit into a device that 
would fit comfortably on a standard lab bench. As a result, one device that can satisfy all above 
requirements is a microcontroller. A microcontroller is a system on chip that has an integrated circuit 
(IC) built inside. A microcontroller has both input and output port peripherals that allows the device to 
communicate with several external devices, which in our case would be the temperature and fluid 
control systems. Moreover, it also has program memory inside that allows the programmer to upload 
digital instructions to execute commands using common programming languages such as C or C++. In 
addition, since we were developing a prototype for proof-of-concept rather than a marketable product, 
we did not want to design our own circuit board or microcontroller to perform aforementioned tasks. As 
a result, one of the most important features needed was a microcontroller board with a user friendly 
integrated development environment (IDE). This IDE could save time by introducing powerful and 
convenient programming functions that allow the team to integrate communication between the 
microcontroller and the temperature and fluid systems without being concerned about how to setup 
the communication protocol between these devices.  
In this section, the team describes some options for microcontroller development board that are 
widely available on market and were considered for this project.  
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4.2.3.1  Arduino Mega 2560  
 
Figure 3 Arduino Mega 2560 microcontroller board  
Retrieved from: https://www.arduino.cc/en/Main/arduinoBoardMega 
The Arduino Mega 2560, seen in Figure 3 above, is a development board that has an 8-bit chip 
ATmega2560 powered by 5 V. This board has 54 digital I/O pins along with 16 analog input pins. This 
number is very impressive since it has a lot of available pins to allow for additional communication with 
the temperature and fluidic systems. The board also has 8 KB of RAM memory with maximum clock 
speed of 16 MHz. Moreover, it has a built-in flash memory of 256 KB that allows user to store the 
program inside the board, even after disconnecting the power to Arduino board. Therefore, whenever 
we turn on this device, our automated system will be on without having to reprogram it. Additionally, 
the Arduino Mega 2560 can be powered through two possible ports of 5 V. One is via USB cable port 
which is a convenient option because it allows us to study the current draw and power consumption of 
the system before selecting an appropriate battery. After we are familiar with how much power the 
system consumes, we can purchase a 5 V battery and connect through Arduino’s battery port, which 
makes the system relatively independent of computer and can become a separate device.  Lastly, 
Arduino LLC has developed its own IDE with the Arduino language. This programming language is a 
higher level version of C/C++ that combines several C/C++ system instructions to communicate with 
devices into simpler and more compact commands for the user. For example, Arduino’s digitalRead() 
function is actually a combination of several C commands such as configuring register pin data being 
read from, accessing ram memory, storing data read from digital pin to memory location and so on. 
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4.2.3.2 MSP430F5529 USB LaunchPad Evaluation Kit 
 Another option for the system’s microcontroller is the MSP430F5529, which is a 16-bit 
microcontroller board from Texas Instruments (TI) and can be seen in Figure 4 below. It is low power 
and connects to a PC through a USB 2.0 port. It supports 40 pins to allow communication with external 
devices. Maximum clock speed 25 mHz with 128 KB flash memory and 8 KB RAM. This board has several 
built-in external devices such as 12-bit analog to digital converter (ADC) and a temperature sensor, 
which are necessary for the thermal function of our system. In terms of hardware efficiency, this board 
is more advanced than the Arduino Mega 2560 since it consumes less power, while supporting powering 
options between 5 V to 3.3 V. Moreover, the higher clock speed can improve the system execution if 
there are too many processes required to be competed simultaneously in the final design. The 12-bit 
ADC also introduces better resolution to the user than the 10-bit ADC of the Arduino Mega 2560, which 
can result in more precise data collection for temperature values or linear actuator syringe data. Similar 
to Arduino, this board also has its own IDE called Code Composer Studio. This is similar to a C/C++ 
program interface that has a built-in driver setup to be compatible with the board. However, this IDE is 
much more advanced than Arduino since it allows user to trace down value in each pin register, setting a 
break point and real time operating system design.  
 
Figure 4 Texas Instruments 16-bit microcontroller board  
Retrieved from: http://www.ti.com/tool/msp-exp430f5529lp 
In terms of hardware consideration, the MSP430F5529 definitely has more benefits than the 
Arduino Mega 2560. It can execute programs faster and it also has more bit range (16 bits) in the core 
than the 8-bit ATmega2560 chip. With more instruction and data bus, the process of making decisions, 
accessing memory, and configuring hardware interface with external devices will be faster. 
MSP430F5529 also has lower price of $13, compared to $40 for the Arduino Mega 2560. However, one 
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significant drawback of MSP430F5529 is that the programming content of TI board is much more 
complicated. It requires the programmer to access each bit of register ports to turn them on or off in 
order to setup different modes of that port, which can be the input port, output port and other 
functions such as internal clock setup. Moreover, to communicate with external devices, the 
programmer needs to know about the protocol associate with it such as SPI, I2C or UART. Setting up the 
drivers for these protocol is complicated and time consuming, which was not suitable for the seven 
week time constrain the team had on the project. Given that time is the most important concern and 
other hardware or price drawbacks are not as significant, the Arduino Mega 2560 was chosen. 
4.2.4 Fluid Control  
Usual fluid control involves applying pressure to push or vacuum the fluid inside a fluid path. 
Therefore, this section discusses what fluid control mechanisms we considered for generating these 
pressure forces while also being compatible with our system requirements.  
4.2.4.1 Pumping Options 
One of the first options the team looked at was a peristaltic pump, which consists of a rotating 
wheel leaning against a tube, as seen in Figure 5 below. These continuous sealing actions against the 
tube result in a vacuum force, which can draw fluids from one end into interior tubing system. When the 
sealing releases pinches at the other end, the fluid will be drawn out. As a result, if we put reagents 
reservoir at one tube end, this pump can deliver them into a microfluidic channel at the other end. In 
terms of automation, by controlling the rotating speed of the wheel, we can manage the flow rate that 
is appropriate for the fluidic systems.  
 
Figure 5 Peristaltic pumping mechanism. 
Retrieved from http://www.verderflex.com/en/how-do-peristaltic-pumps-work/ 
Another option is torque-actuated pump. This design, seen in Figure 6, is from the Hong Kong 
University journal. The system has a screw in red and a base in grey. The base has threads that allow the 
screw to introduce fluid into the system. When the screw is rotated clockwise, the solution flows from 
the red section into a microfluidic channel; when the screw is rotated counterclockwise, the fluid in the 
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microfluidic channel is vacuumed back into the reservoir. One advantage of this system is its compact 
and simple design. Moreover, this design is suitable for a microfluidic system, which is one of the most 
challenging feature of our desired system. The main drawback is that since the screw system is manually 
controlled, we would have to create an external piece that can attach to the screw to automate it. 
Moreover, since the design is not off-the-shelf it would require selecting appropriate materials to 3D 
print. 
 
Figure 6 Torque-actuated pump 
Retrieved from https://www.researchgate.net/publication/286652883_Simple_Cost-
Effective_3D_Printed_Microfluidic_Components_for_Disposable_Point-of-Care_Colorimetric_Analysis 
Lastly, the syringe pump is one of the most popular pumping techniques. As seen in Figure 7, the 
syringe plunger usually attaches to a linear actuator that is capable of shortening and expanding. These 
actions of compressing and expanding will result in push and pull actions on syringe plunger, thereby 
allowing for the intake or output fluids from the syringe. The movable linear actuator is usually driven by 
a motor with controllable pumping or vacuuming speed. One of the advantages of the syringe pump is 
its friendly interface with the linear actuator, which is available off-the-shelf product. The design is fairly 
simple, yet can maintain good accuracy of fluid dispensing.   
Given the short amount of time and for the sake of the proof-of-concept, the team wanted to 
choose a design that consists of widely available OTS components. This requirement, however, does not 
fit well to either the peristaltic or torque actuated pumps. Both of these would require external 
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mechanical parts to allow for automation of the pumps which would also require many calculations and 
experiments before the system would become usable. Moreover, for the peristaltic pump, the rotating 
wheel is not a popular component and therefore the team would most likely have to design and 3D print 
the appropriate piece. As a result, the syringe pump was chosen. This choice was made because syringes 
and linear actuators are easily bought OTS and the interface between these components is straight 
forward and easy to control. 
 
Figure 7 Typical OTS automated syringe pump. 
Retrieved from: http://www.kdscientific.com/products/infusion-syringe-pumps.html 
4.2.4.2 Motor  
After careful consideration, the team determined that in order to generate pressure force into 
the fluidic path, we needed to have an automated push/pull mechanism. These types of automation 
usually involve the usage of motor control. There are several motor options available on the market and 
we had to decide on which is our best option. Below are three of the most popular motor options 
available: 
A DC motor is based on continuous shaft rotation motor driven by DC voltage signal through 
power and ground connection only. This power signal is usually controlled by Pulse Width Modulation 
(PWM) signal. PWM signal with more duty cycles will result in more power delivered to the motor, 
increasing the motor’s speed and force. This motor is the most simple and easiest to drive with only 
relays. However, the shaft progression only stops when power is off, which can result in errors. 
Servo motors are usually DC motors with external components such as a control circuit and 
position sensor to facilitate more precise actuating. Servo motors do not rotate freely but are based on a 
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control input signal. This control signal commands the DC motor when to stop rotating and stay at the 
desired position. This will prevent any external forces that can push or pull the actuator, thereby 
preventing possible error during operations. PWM is also used to control the servo motor operations.  
Stepper motor uses a base motor that has several toothed electromagnets with a central gear in 
between. Similar to servomotor, stepper motor has external circuit to control each electromagnet, 
thereby turning the motor shaft. This electromagnet control is simply switching power on or off to 
energize and cause rotation from one electromagnet to the adjacent one, which is called a step. 
Therefore, the precision of motor rotation is higher with separate electromagnets arranged in one full 
circle. Moreover, this design allows stepper motor to hold position by torque rather than power like the 
DC motor or servo motor, thereby introducing less error and less energy consumption. 
With the purpose for proof-of-concept, which requires control of current draw to the linear 
actuator as well as control of the linear actuator position, the servo motor is the most ideal one. Servo 
motors usually include both a position sensor and a current sensor that the DC motor does not have. 
These sensors record important information that is necessary to select the proper moving range and 
moving speed for dispensing and inputting reagents into fluidic system. In addition, the simpler rotary 
mechanism of servo motor comparing to the more complicated mechanism of stepper motors can 
facilitate our short project time.  
4.2.4.3 Syringe Pump Motor 
One important requirement for the motor was that it should be compatible with an Arduino 
motor driver controller board that is available on the market, which means the sensor signal should be 
within the maximum voltage range of Arduino (5 V). To satisfy this requirement, the team selected an 
Actuonix P16 linear actuator. The P16 is among the most popular and cost effective devices that 
combines both linear actuator and servo motor. This product, seen in Figure 8, requires 12 V DC to allow 
push/pull operations with built-in position feedback. The feedback system consists of a simple 
potentiometer wiper with 5 V power to a positive reference rail and ground to a negative reference rail.   
 
Figure 8 Actuonix P16 linear actuator chosen for syringe pump Retrieved from 
https://s3.amazonaws.com/actuonix/Actuonix+P16+Datasheet.pdf 
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The steel bar is an actuator attached to a servo motor. This bar can move in and out, thereby 
pushing or pulling a syringe plunger if it is attached to the actuator. The electrical wires include power 
and ground wires. There are also position feedback wires that can feed data into Arduino analog pin to 
keep track of the position of steel bar. The distance information is sampled through a 10-bit DAC built in 
the device, which is capable of reporting actuator position in the range from 0 to 210. These numbers 
are the values will be reported from sensor to microcontroller and 210 represents the largest distance 
the P16 can travel, which is 50 mm. 
4.2.4.4 Solenoid Valve Manifold 
One concern we had when we were working on the prototype was how to reduce the size of the 
device as much as possible. Therefore, it was undesirable to a have a single syringe pump to handle one 
reagent only. For the assays of concern in this project, there can be up to eight different reagents that 
need to be dispensed but having eight syringe pumps is undesirable. As a result, we needed to have a 
mechanical part that can act as an interface between one syringe pump and several reagent reservoirs. 
After inquiring with TRT employees, we were able to find a part, the NResearch solenoid valve manifold 
which is available OTS, in an onsite lab and readily available for use. 
 
Figure 9 NResearch Solenoid valve manifold  
Retrieved from: http://www.nresearch.com/ 
As we can see from Figure 9 above, this piece is 12 V solenoid valve manifold from NResearch. 
The manifold consists of four 3-way solenoid valves. Each hole, seen on the front side of the manifold, 
are input channels which would attach via tubing to reagent reservoirs. There are also input and output 
holes at the top and bottom of white part that we cannot see in this picture. These solenoid valves are 
controlled by applying 12 V DC power to two power lines, resulting in an on or off state. As a result, by 
connecting four reservoirs to four side channels, with the syringe pump connected to the input hole and 
an assay plate at the output hole, we can utilize only one syringe pump to deliver four reagents to a 
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well. We were informed that NResearch can customize their products so this piece could be 
implemented with as many as eight valves in order to control all eight reagents through only one syringe 
pump. However, that is the goal for future. For our purpose of proof-of-concept, we decided to make us 
of the available four-way solenoid valves manifold in the TRT lab and justify how well it can work in our 
system. However, another problem arose since these solenoid valves operate at 12 V, which is too large 
compared to our Arduino Mega 2560 pin’s maximum voltage rate of 5 V. However, NResearch also 
provides electronic drivers along with the solenoid valves, which are the CoolDrive One Single Valve 
Drivers. 
 
Figure 10 CoolDrive One single valve drivers  
Retrieved from: http://www.nresearch.com/Images/Drivers/CoolDriveONE.pdf 
This driver, seen in Figure 10, is a printed circuit board with IC chips built-in that can regulate 12 
V power delivered from power supply to the solenoid valve driver. In the driver, there is logic chip that 
accepts 5 V digital signal from Arduino pin. The board basically then acts like a switch. If it receives 5 V 
from digital output of Arduino, it closes the switch and allows 12 V power to pass through. If it receives 
less than 0.8 V, it disconnects the switch and solenoid valve turns off. 
4.2.5 Temperature Control 
For the temperature control subsystem of our prototype, the team had to consider a number of 
different heating and cooling mechanisms to accurately control the incubation environment for the 
assays. The various options that were considered are discussed in the following sections. 
4.2.5.1 Kapton heaters 
The first option for temperature control was inherited from previous TRT work on this project, 
where they chose to use Kapton polyimide film, seen in Figure 11, from OMEGA Engineering Inc., 
attached to aluminum blocks as a heat source. This was used in parallel with a Minco CT325 microheater 
controller which utilized a RTD/thermistor sensor to better control the temperature. The operating 
voltage range is 4.75 V to 60 V DC while RTD input should be from 100 Ω to 1000 Ω and the thermistor 
input should be 50 kΩ. The power source provides energy to heater up to 240 watts and the RTD sensor 
39 
 
can detect temperature from 2° C to 200° C. The thermistor can detect temperature from 25° C to 75° C. 
The temperature is read with a voltmeter connecting to the left-most two pins with calibration of 0.010 
V/°C.  
 
Figure 11 Kapton heater  
Retrieved from: http://www.omega.com/pptst/KHR_KHLV_KH.html  
The Minco controller delivers power through red electrical wire to a dark orange thermofoil. 
These thermofoils are taped to a metal bar, which converts electrical power to heat. By controlling the 
amount of current delivered to the metal bar, the temperature can be adjusted. The entire temperature 
control setup can be seen in Figure 12 below.  
 
Figure 12 Potential heating system created by TRT team 
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However, the film has an area of 1 in x 3 in and energy density of 10 W/in2 and 115 V power. 
Since it has such a high voltage requirement, it was expected that it would take a significant amount of 
time to reach the desired temperature when connected to the 20 V power supply.  
4.2.5.2 Peltier Thermoelectric Heating and Cooling  
One of the most popular heat control method is the Peltier TEC module, seen in Figure 13. The 
Peltier TEC makes use of the Peltier effect to generate heat flux across a p-n junction. The p-n junction is 
sandwiched between two ceramic plates, where one plate is bonded to the hot side of Peltier and the 
other is bonded to the cold side. When the Peltier module is provided with electrical energy, it will heat 
up one side and cool the other side. Moreover, this hot and cold effect can be opposite if we reverse the 
polarity of delivered energy. One of the most popular as well as reasonably priced Peltier modules is the 
TEC1-12706. It has dimensions of 40 x 40 x 3.8 mm and can operate from -30 °C to 83 °C, which includes 
all temperatures required for this project. The max voltage allowed is 12 V with a corresponding max 
current draw of 6.1 A.  
 
Figure 13 Peltier TEC module  
Retrieved from: https://www.amazon.com/TEC1-12706-Thermoelectric-Peltier-Cooler-Volt/dp/B002UQQ3Q2 
When used to heat an 82 x 34 x10 mm aluminum bar, the previously mentioned Kapton heater 
took almost 20 minutes to heat the block from room temperature (24 °C) to 37 °C. Since we needed the 
temperature transition to take less than five minutes, the Kapton heater option was discarded because of 
this long temperature change time. The group then tested the Peltier TEC to determine if the time for 
temperature change could be less than that of the Kapton heater. By attaching the hot side of the module 
to the same sized aluminum bars, the Peltier could heat up the aluminum bar from room temperature (24 
°C) to 37 °C in two minutes and from room temperature (24 °C) to 65 °C in five minutes. With this 
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preliminary sample data, we concluded that the Peltier TEC module was appropriate for our design 
requirements. The TEC can also produce cold in order to stop the heating process and cool down the 
aluminum block back down to room temperature, which was another requirement for the heating system. 
This could speed up the cooling process compared to passive cooling that would be the method cooling 
used if the Kapton polyimide film heaters were selected. Finally, the TEC module is much cheaper than 
the polyimide film. As a result, with considerations of efficiency, price, and availability, we decided to 
select the TEC1 12706 Peltier TEC module as the temperature source. 
4.2.5.3 Temperature Sensor 
The device also required a temperature sensor to show the actual temperature of the heating 
block during the temperature control process. We wanted a sensor that can operate within the range of 
our assay temperatures, meaning it would have to maintain good performance at and beyond 65° C. 
Moreover, the temperature should communicate easily with the Arduino without requiring further 
implement of a driver setup or other communication protocol. One of the most popular and cost 
effective temperature sensors is the LM35, which can be seen in Figure 14.  
 
Figure 14 Temperature Sensor Retrieved from 
www.google.com/search?q=lm35&rlz=1C1CHFX_enUS608US608&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiZvcr70ZrTAh
VM2SYKHTgxDfAQ_AUIBigB&biw=1270&bih=633#imgrc=dCxcZGTs1zyamM: 
This LM35 temperature sensor has an operation range from -55 °C to 150 °C, which is much larger 
than our maximum temperature requirement of 65° C. It also has a 0.5 °C accuracy at the ambient room 
temperature of 25 °C, which is adequate for our purpose of proof-of-concept. Moreover, current 
consumption of this sensor is only 60 μA and operating voltage ranges from 4 V to 30 V. Finally, it has 
simple communication with the Arduino via the analog input pin. 
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4.2.6 Heat and Fluid Controller Driver 
After consideration and selection, we had chosen the three most important components for the system:  
o Arduino Mega 2560 is the brain of the system, carrying out instructions to communicate 
and gather data from peripheral devices.  
o P16 Linear Actuator, which will be attached to a syringe holder that can push or pull the 
syringe plunger to handle fluidic flow. Position data will feed back to the Arduino serial 
monitor and will be used to correspond how much volume associates with distance 
traveled. 
o Peltier TEC module is used to generate heat to the metal block. The amount of heat or 
cold generated will be determined through power magnitude that we provide to the 
Peltier TEC module.  
However, one problem in this design was that P16 Linear actuator requires 12 V power, while the 
Peltier TEC requires 8 V. Both these values exceed the 5 V limit of the Arduino and if they are connected 
directly to the Arduino pins, the Arduino will be immediately and irreparably damaged. Therefore, we 
needed an interface between the Arduino and these devices to regulate the power through the 5 V 
instructions of the Arduino. Moreover, another common feature between these two devices is that they 
need to be able to reverse and forward the polarity of voltage applied to them. For the linear actuator, 
forward drives the steel bar out, vacuuming the reagents into fluidic system, and reverse drives the steel 
bar in, dispensing the reagents to the 96-well plate. For the Peltier TEC module, forward makes the site 
facing the metal block heat up, and reverse makes that same site cool down, bringing the metal block 
back to room temperature (24° C). One of the most common circuitry that allows for this specification is 
an H-Bridge. Conveniently, we were able to retrieve an OTS motor driver controller board, a Pololu Dual 
MC33926 Motor Driver Shield for Arduino, from the TRT lab, seen in Figure 15 below.  
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Figure 15 MC33926 Motor driver shield for Arduino microcontroller board  
Retrieved from: https://www.pololu.com/product/2503 
This driver board can handle voltage from 5 V to 28 V delivered to external devices and has a 
current limit draw of 3 A, while the maximum voltage for the actuator is only 12 V. With this number, we 
were not afraid of current overload with the 6 A breakdown limit of Peltier TEC module that can damage 
the Peltier. Moreover, this driver board is compatible with Arduino and therefore the board can be 
powered through the 5 V pin from the Arduino and receive the Arduino command to increase or decrease 
current draw to devices, and forward or reverse energy polarity to meet requirements. One of the most 
significant features of this board is its robust drivers that can limit over current draw, over temperature 
shutdown, under voltage shutdown, and short circuit protection. All of these power protections are not 
present in the Arduino, which is why the Arduino is very sensitive to power surge, which can damage the 
board. Finally, Pololu created a library that simplifies communication protocol between the Arduino and 
the MC33926 board. The user only needs to call a single line of code to control delivered power and power 
polarity which saves a significant amount of time in integrating the system using this motor driver board.  
4.2.7 Control Mechanism 
One problem with the Peltier TEC module was that if it continually received full energy draw from 
the power supply, it would continue to heat up and will eventually reach its max operating temperature 
and break. Moreover, we wanted to keep the system to be stable at specific assay temperature of 37 °C 
and 65 °C. Lastly, it was desirable to not only heat up the metal bar but also cool it down to room 
temperature (24 °C) or even below for future application of freezing samples. As a result, we needed an 
automated controlling method that can vary energy delivery to the Peltier module as well as be able to 
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reverse that power so as to cool down the metal bar. There were two iterations on this part:  One was to 
use power relay. The relay is an electrical component that acts like a toggle switch (turning on and off the 
power) with more advanced feature: built-in voltage regulation for preventing power surge which can be 
automated through a microcontroller. It is also one of the most common mechanisms for temperature 
control in a standard house thermostat: If we use a heater and want to reach 40° C, the thermostat tracks 
the temperature sensor until it reaches 40° C and switches off power relay. If the temperature is below 
40 °C, relay will be switched on. This on-off mechanism, however, does not meet with our product 
requirement closely. Since we need the temperature to only have a tolerance of ±1 °C, turning on and off 
power cannot do it. This is because if we turn off the heater, while being full powered, at 40 °C, the metal 
block still has internal heat remains that can keep increasing the block temperature far off.  Moreover, 
relay cannot support the function of reversing power polarity but only passive cooling. As a result, we 
needed to come up with an option that can reverse power polarity and when the block temperature is 
approaching the desired temperature, lower the current draw from power supply. Therefore, since our 
goal was to automatically adjust the control value, the team implemented a PID control mechanism. 
4.2.7.1 PID explanation 
 
Figure 16 PID Control Loop  
Retrieved from:  http://machinedesign.com/sensors/introduction-pid-control 
PID is also known as a Proportional, Integral, and Derivative control loop, which are widely used 
currently. An example of this control loop can be seen in Figure 16. One popular control loop concept in 
daily life is driving car. When you are driving your car, if you are reaching your destination, you see your 
speedometer is at 65 mph and you want to slow down to 30 mph, 20 mph and then 0. The less offset 
distance you are away from the destination, the less speed you want your car to have and vice versa.  As 
a result, your eyes, speedometer, foot, and gas pedal form a control loop that allows you to adjust the 
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car speed properly. In a similar way, the PID controller computes the output (speed) to be based on the 
input error of travel distance. In PID, we can control three parameters: 
 Proportional factor: This factor controls the regulated output by multiplying the measured input 
error and a certain gain factor. This control type allows the system, if far away from desired 
goal, to approach the goal faster. However, one problem is if the gain factor is too large, it can 
cause overshoot, meaning that the system can go above the desired goal level. In addition, it 
takes long time for system to stabilize from that oscillation. Moreover, when error is small, the 
control loop cannot detect it well and barely any output appears. Therefore, for a more accurate 
control system, using proportional factor alone is not enough.  
 Integral factor: This factor considers the offset error and duration of offset. From that, the 
integral factor integrates the error over time and based on that sum, changes output to reduce 
that error sum of the previous calculation. On the other side, as the ‘I’ factor takes into 
consideration of past error, it can result in overshoot to the desired goal.  
 Derivative factor: This generates a rate of error instantaneously and computes the product of 
that rate with a certain gain factor. The derivative factor deals with how fast the error is 
changing over time so it can compensate the stability of the control system. Therefore, we can 
use this factor for stabilizing the system but not for approaching desired goal fast as 
proportional system.  
Since our heating systems has requirements of reaching assay temperature (37 °C, 65 °C, room 
temperature (24 °C) with an offset allowance of 2 °C, we only consider proportional factor since it can 
satisfy above goals while also being the easiest factor to tune. 
4.3 Feasibility Studies and Experimental Modeling  
4.3.1 Fluidic Control System Modeling  
Because of the nature of the requirements for this project, it was difficult to perform a feasibility 
study on the fluidic control portion of the device. Because of the early stage and proof-of-concept 
nature of the device, there was no specification for flowrate, time of fluid control, tubing diameter, size 
constraints, or other such areas of concern. As such, the feasibility of the device had to be determined 
through empirical and experimental methods. However, the team did analyze the solenoid valve 
manifold system to determine what effects the internal pathway of the valve manifold used would have 
on the system by creating spaces for fluid dead volumes and cross contamination. Later in the project, 
we found through experimentation that this value was not consistent and varied with different 
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conditions. The architecture of the valve manifold can be seen in Figure 17 and full calculations are 
below.  
 
Figure 17 NResearch valve manifold technical drawing: modified by MQP team to highlight path lengths  
Retrieved from http://www.nresearch.com/ 
In order to calculate or analyze the internal pathway in the solenoid valve manifold, the 
following steps were performed. In order to calculate the total length of the common passage, the 
length of the common passage consisting of diagonal path was calculated.  
Length of common passage (Diagonal paths= x, x/2) 
x =√0.662 + 0.662 = 0.93 in 
x/2 = 0.467 in 
Total Length of the common passage can be calculated by using the following equation: 
=  (x*3)+(x/2*2)=  (0.93*3)+(0.467*2) in  =   3.72 in 
 
Inlet Passages consists of horizontal and vertical lengths. In order to calculate the total length of the 
inlet Passage, both the horizontal and the vertical lengths were added.  
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Horizontal length= 0.66/2 = 0.33 in 
Vertical length= 0.81/2= 0.406 in 
 
Total Length of the Inlet passage can be calculated by using the following equation:  
=(vertical length of each inlet passage +horizontal length of each inlet passage)*4  
=(0.406+0.33)*4 = 2.944 in 
Internal Volume for the common passage = 91 uL (Given in the drawing) 
Internal Volume each inlet port = 32.5 uL (Given in the drawing) 
 
The area of the common passage can be calculated by dividing total volume by total length. The 
following equation was used to calculate the area of common passage: 
Area of the common passage (𝐴1) = Total Volume/Total Length = 91 uL/ 3.72 in    
= 0.00556 𝑖𝑛3/ 3.72 in = 0.00149 𝒊𝒏𝟐 
 
The diameter of the common passage was calculated by using the area of the common passage. 
Diameter of the common passage 
= √(4 ∗ 𝐴1)/𝜋 = √(4 ∗ 0.0014)/𝜋= 0.042 in 
 
Similarly, the area and diameter of the inlet passage was calculated using the following equations: 
Area of each inlet (𝐴2) = Volume in each inlet passage/ Length of each inlet passage 
= 32.5uL/0.736in = 0.0198 𝑖𝑛3/ 0.736 in = 0.0269 𝒊𝒏𝟐 
 
Diameter of each inlet= √(4 ∗ 𝐴2)/𝜋 = √(4 ∗ 0.0269)/𝜋 = 0.185 in 
Since resistance of the flow is directly proportional to length, the team tried to reduce the length of the 
wire tube connecting the manifold. The team used 1/32 in diameter tube. In order to lower the 
resistance of the flow, the smaller diameter tube can be used for the prototype.  
4.3.2 Temperature Control System Modelling  
The general idea was to heat the 96-well plate with samples inside by placing it on a heat-
conducting platform. This platform would be required to be a good conductor, easily machined, and 
simple to interface with a 96-well plate. The first step in this process was selecting material for the 
heating platform. Two of the most common heat-conducting materials are aluminum and copper. 
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Therefore, it was important to carry out a rough analysis on the heat conduction characteristics, namely, 
how fast the material can heat up 96-well plate from room temperature (24° C) to the final desired assay 
temperature of 37 °C and 65 °C as well as how fast can it cool the 96-well plate from the desired assay 
temperature back to room temperature. Lastly, given the selected material, it was necessary to decide 
on how to machine the metal block so that it could facilitate heat conduction between the Peltier TEC 
module and the block, and between the block and the 96-well plate. Given our short time range at TRT, 
we cannot conduct all testing to determine which part to choose or which material to choose. 
Therefore, this modelling section would provide theoretical calculation that can help us select an option 
without experimental testing. This gave us an educated starting point and provided more insight for 
future improvement.  
4.3.2.1 Transient Model for Heating: Aluminum vs. Copper 
First, a modelling for transient response of how temperature versus time behavior between 
copper and aluminum was conducted. In this model, we used the transient equation as follows: 
Ɵ =
𝐸𝑖𝑛
h ∗ A
+ (Ɵ𝑖 −
𝐸𝑖𝑛
h ∗ A
) ∗ 𝑒−𝑡/𝑇𝑎𝑢 
Ɵ is the temperature difference between current temperature and ambient temperature, which 
was chosen to be 25 °C. Ɵi is the initial temperature difference which we assumed was 0 °C because the 
metal block had remained at room temperature for some time. Ein is power delivered to the Peltier TEC 
module. Since we used 8 V from power supply and we had 1.5 A current draw on average, the energy 
value was calculated as: 
𝐸𝑛𝑒𝑟𝑔𝑦 = 𝑉 ∗ 𝐼 = 8 ∗ 1.5 = 12 𝑊𝑎𝑡𝑡𝑠 
For the purpose of proof-of-concept, we only used three rows of wells, each row having eight 
wells, for each assay. Therefore, to reduce the time and effort in machining metal block, we chose the 
size of block that could fit three rows of wells. The dimension found by rough estimation gave the area 
of metal block as 0.006954 m2. The value h is a heat transfer coefficient, which were advised by a 
mechanical engineer in TRT to be 30 
W
K∗m2.
. Tau value in here represents time versus temperature 
relationship of different metals. The equation we used for tau calculation was: 
Tau =
m ∗ c
h ∗ A
 
Tau calculated for aluminum was 196.29 seconds and for copper was 278 seconds. The variable 
m is the mass of the metal block. The mass of the aluminum block was chosen to be 0.045 kg and the 
mass of copper block was chosen to be 0.15 kg. These mass values were calculated using the same area 
of 0.006954 m2 as above. C is the specific heat capacity value for copper and aluminum, which are 390 
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J
Kg∗K.
 and 910 
J
Kg∗K.
 respectively. Putting those values into above Ɵ transient equation, we could find the 
temperature of metal block by: 
𝑀𝑒𝑡𝑎𝑙 𝑇𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 = Ɵ + Initial Metal Temperature =  Ɵ + 25 
 
 
Figure 18 Transient Response: Heat Input and Convection of Aluminum vs. Copper 
As we can see from Figure 18 above, aluminum in red takes less time to heat up than copper in 
blue. From this graph, we predicted that aluminum can bring the heat station from room temperature 
(24 °C) to assay temperature faster than copper. However, it was also required to make sure that the 
system is capable of returning to room temperature since there are assay steps incubating samples at 
room temperature. As a result, the following section will study the cooling capability between the two 
materials before making decision. 
4.3.2.2 Transient Model for Cooling: Aluminum vs. Copper 
In this model, we used the transient equation based on Newton’s law of cooling as follows: 
𝑇(𝑡) =  𝑇𝑒𝑛𝑣 + (𝑇(0) − 𝑇𝑒𝑛𝑣) ∗ 𝑒−
𝑡
𝑡0 
The ambient temperature (Tenv) was chosen to be 22 °C based on room temperature in TRT 
station at that time. The block was assumed to be near 54 °C at the beginning (T(0)). All other values, 
such as heat coefficient and tau values were kept the same as the previous modelling. Putting these 
numbers into T(t) equation, we had cooling characteristics of aluminum and copper as seen in the graph 
below. 
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Figure 19 Transient Cooling Response of aluminum versus copper 
As we can see from Figure 19 above, aluminum in blue cools down faster than copper in red 
from 54° C. From these cooling and heating experiments, testing with both aluminum and copper blocks 
with the same surface area and thickness, we concluded that aluminum can both heat up and cool down 
faster than copper. Therefore, aluminum was chosen as the material for heating station.  
4.3.2.3 Thermal Conductance Circuit 
After selecting aluminum as the material for the heating block, it was important to decide how 
we should machine the metal block to facilitate the best heat conduction between the metal block and 
the 96-well plate. The first idea was to use a thin aluminum sheet as can be seen from the diagram 
below. In this method, we would attach the Peltier TEC module to one end of the block surface so it can 
transfer the heat to the aluminum sheet and then place the polystyrene well plate onto the sheet, near 
the Peltier TEC. We will justify this configuration’s thermal resistance in a generalized system. It should 
be noted that for the purpose of simplicity of the model, air resistance was disregarded and thermal 
contact conductance was assumed to have one constant value of 20000 
W
K∗m2.
, which was advised by a 
TRT mechanical engineer. Moreover, since the internal design of Peltier TEC is a p-n junction, which is 
complicated to model, we also disregarded the Peltier TEC internal heat resistance.  
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Figure 20 Thermal circuit of aluminum sheet with polystyrene well 
A typical thermal system usually breaks down into a resistance circuit similar to an electrical 
resistor circuit and can be used to study thermal behavior. The heat source, similar to a power source, 
delivers energy through several blocks of resistances. In our system, the thermal resistance circuit 
represents how much of the original heat will remain after going through the Peltier-metal block contact 
resistance, internal metal block resistance, and so on until it reaches the output. The output of this 
system is the temperature inside the polystyrene wall. As we can see from Figure 20 above, we have 
four resistors in series. We can calculate the value of each resistance as following: 
 RAB: Peltier-Aluminum sheet thermal contact resistance. Hc is the thermal contact 
conductance is: 20000 
W
K∗m2.
. A is the surface area of Peltier TEC module. From that, we can 
find the thermal contact resistance with our Peltier TEC module area as: 
𝑅𝑃𝑒𝑙𝑡𝑖𝑒𝑟𝐶𝑜𝑛𝑡𝑎𝑐𝑡 =  
1
ℎ𝑐 ∗ 𝐴
=
1
20000 ∗ 0.0016
= 0.03125 
𝐾
𝑊
 
 RBC: Aluminum sheet thermal conductance across the sheet for the heat to transfer from 
Peltier TEC to the well plate position. This can be calculated using following equation: 
𝑅𝑆ℎ𝑒𝑒𝑡 =  
𝑥
𝐴 ∗ 𝑘
=  6.9686 
𝐾
𝑊
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In this equation, x is length of material that is parallel to heat flow, which we found to be 0.035 
m. K is thermal conductivity of material. For aluminum, this number is 205 
W
K∗m.
. A is the cross-sectional 
area that is perpendicular to heat transfer flow, which in our case is, 0.0000245 m2.  
 RCD: Aluminum sheet – single polystyrene well thermal contact resistance. In here we have 
the similar equation as above: 
𝑅𝐶𝑜𝑛𝑡𝑎𝑐𝑡 =  
1
ℎ𝑐 ∗ 𝐴
=
1
20000 ∗ 1.01203 ∗ 𝑒−5
= 4.94055 
𝐾
𝑊
 
 RDE: This is the thermal resistance for the heat to travel across the polystyrene wall of well 
plate to reach the water/solution inside the well.  
𝑅𝑃𝑜𝑙𝑦𝑠𝑡𝑦𝑟𝑒𝑛𝑒 =  
𝑥
𝐴 ∗ 𝑘
=  933.083 
𝐾
𝑊
 
Here we assumed that the temperature right at the inner layer of the polystyrene well will be 
the same as that of the fluid contained in the well in order to simplify our calculation. The system, 
starting from RAB and ending at RDE, is a series of thermal resistors with the end of each resistor as the 
start of next resistor. With this series resistance circuit, we can calculate the total thermal resistance by 
adding up RAB, RBC, RCD and RDE to be 945.023  
𝐾 
𝑊
 for the first set up of heat block.  
In the second setup, instead of a thin aluminum sheet, we used a thicker metal block in which 
we drilled holes that could hold the wells and reach halfway up the well wall. The same simplification for 
the thermal system analysis was kept similar to the above setup.  
 
Figure 21 Thermal circuit of a machined aluminum bar and polystyrene well 
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As we can see from Figure 21 above, we have four resistors in series with each other. We 
can calculate the value of each resistance value as follow: 
 RAB: Peltier-Aluminum block thermal contact resistance. We can find the thermal contact 
resistance with our Peltier TEC module area as: 
𝑅𝑃𝑒𝑙𝑡𝑖𝑒𝑟𝐶𝑜𝑛𝑡𝑎𝑐𝑡 =  
1
ℎ𝑐 ∗ 𝐴
=
1
20000 ∗ 0.0016
= 0.03125 
𝐾
𝑊
 
 RBC: Aluminum sheet thermal conductance across the sheet for the heat to transfer from the 
Peltier TEC to the well plate. This can be calculated using following equation: 
𝑅𝑆ℎ𝑒𝑒𝑡 =  
𝑥
𝐴 ∗ 𝑘
=  0.813 
𝐾
𝑊
 
 RCD: Aluminum block – single polystyrene well thermal contact resistance. Here we have similar 
equation as above: 
𝑅𝐶𝑜𝑛𝑡𝑎𝑐𝑡 =  
1
ℎ𝑐 ∗ 𝐴
=
1
20000 ∗ 0.00021
= 0.41 
𝐾
𝑊
   
 RDE: This is the thermal resistance for the heat to travel across the polystyrene wall of well plate 
to reach the water/solution inside the well.  
𝑅𝑃𝑜𝑙𝑦𝑠𝑡𝑦𝑟𝑒𝑛𝑒 =  
𝑥
𝐴 ∗ 𝑘
=  409.96 
𝐾
𝑊
 
The second system is also a series of thermal resistors. We can calculate the total thermal resistance by 
adding up RAB, RBC, RCD and RDE, whose sum ends up with the total thermal resistance of 411.216 
𝐾
𝑊
 for the second set up of the heat block.  
As we can see after calculating the value for each heat block setup, even though we have a thicker 
metal block for second setup, it only results in 411.216 
𝐾
𝑊
 compared to 945.023 
𝐾
𝑊
 from the first setup. 
The second configuration is only 43.5% resistance compared to the first one. This difference is because 
when we introduce more contact area between the aluminum block and polystyrene well by insertion, 
we facilitate more heat transfer between them. Therefore, the contact area increases, thereby decreasing 
the thermal resistance value. Moreover, by fitting each well into metal block, each polystyrene row can 
be kept more tightly rather than taping into aluminum sheet like in setup one. As a result, we decided to 
select the second setup for the heat station. 
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4.4 Final Design Approach 
4.4.1 Prototype Architecture  
After creating an ideal system architecture, the team also created a basic architecture drawing 
of the prototype system itself to have a simplified view of the various subsystems that made up the 
device. This representation can be seen in Figure 22 below.  
 
Figure 22 Prototype Architecture 
4.4.2 Assay Selection 
In order to meet our objective to create a prototype device, which could perform multiplexed 
assay for the cells, our team looked into different potential substances (contaminants) affecting MSCs 
during quality control.  To accomplish this goal, the team researched various OTS assay kits for 
mycoplasma, trypsin, endotoxin and BSA. Due to the time constraints of the seven week term and for 
the sake of proof-of-concept, only mycoplasma and BSA Assay kits were chosen, with the thought that 
other assays could be implemented in the future. Though a number of manufacturers sell assay kits to 
detect these contaminants, they differ in terms of sensitivity, time to run the assay, cost, read-outs, 
temperature, and procedure steps for the assay. After comparing these parameters, the most similar 
assay kits were chosen based on parameters like read-outs and procedure steps. The comparison tables 
for both OTS shelf assays can be seen in Table 2 and Table 3 below; the team’s choices for each assay 
are indicated by italics. 
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Table 2 OTS BSA Assay Tradeoff Analysis 
Parameter Cygnus Technologies  MyBioSource 
Sensitivity 0.124 ng/mL 85.5 ng/mL 
Time 2 hours  2 hours 
Cost $525 $430 
Principle ELISA  ELISA 
Read-out Absorbance Absorbance  
Sample Preparation Sample dilution Supernate preparation 
 
Table 3 OTS Mycoplasma Tradeoff Analysis 
Parameter  Roche Thermo 
Fisher 
ATCC R&D Systems 
Sensitivity 10 CFU/mL 4 CFU/mL Unavailable 15 CFU/mL 
Time 5 hours 5 hours Unavailable 4.5 hours 
Cost $1000  $3000 Unavailable $380 
Principle Polymerase Chain 
Reaction (PCR) 
PCR  PCR DNA 
hybridization/ELISA 
Read-Out Fluorescence, 
impedance 
Fluorescence Fluorescence, 
impedance 
Absorbance 
Sample Preparation Lysis solution Lysis solution Lysis solution  Lysis solution 
 
Additionally, the chosen kits came with precoated assay plates, appropriate for each assay. 
These assay plates were in stripwell form so the team could continue with the goal of using only the 
necessary amount of wells for each assay run. It also allowed for easy transfer to a standard absorbance 
microplate reader.  
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4.4.3 Fluid Control 
After extensive iterations and analysis of potential components, the team chose appropriate 
components to make up the final fluid control subsystem. The system can be seen in Figure 23 below.
 
Figure 23 Fluid control system consisting of syringe pump and solenoid valve manifold 
After the previously discussed iterations and research, the team decided to utilize a simple 
syringe pump system that was created in house at TRT. This syringe pump consisted of a machined 
aluminum platform that supported a Hamilton gas tight 1 mL syringe. The glass syringe plunger is 
attached to a P16 Actuonix linear actuator. At the syringe tip, we connected 1/32 in outer diameter 
tubing into the NResearch solenoid valve manifold, which was controlled by the CoolDrive One Single 
Valve Driver. The whole system was controlled through the MC33926 motor driver shield from Pololu 
and an Arduino microcontroller board. This option for fluid control was chosen because of its immediate 
availability and simple design that would lead to minimizing testing time and more thoroughly showing 
proof-of-concept for the device. An in-house pump was used because of the cost and time it would 
require to purchase an OTS pump; however, if a syringe pump was used in the future for the final design 
of the device, a much more precise and well-manufactured pump would be used instead. 
The fluid control system also consisted of a removable vacuum pump that was used to flush the 
system between additions of reagents. This pump remained removable and was only attached to the 
system when needed because of difficulty had with attaching the pump without adding large amounts 
of excess tubing pathways. This pump was retrieved from a TRT lab and was controlled by a direct 
connection to a 12 V power source. 
Syringe Pump 
Arduino Control 
Setup 
Solenoid Valve 
Manifold 
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4.4.3.1 Fluid Control System Schematic  
 
Figure 24 Schematic showing control of syringe pump and valve manifold system 
The schematic, seen in Figure 24, was drawn using Fritzing software, which is an open-source 
tool online that allows the user to draw schematics for the Arduino and the most popular Arduino 
components. From the above figure, we show a more detailed representation about how each 
component communicates with each other. Here the MC33926 Motor controller Arduino Shield is 
replaced with a MD03A Motor Driver since there is not schematics library for the MC33926 version and 
the MD03A is the closest match inside software library. Therefore, we replaced the MD03A as our motor 
driver and specified the correct name in the picture. As we can see on the motor driver board, the two 
ports in middle are connected to a 12 V power source so as to drive the P16 Actuonix Linear Actuator 
through two top terminals. By sending commands from the Arduino to the motor driver to the M1PWM 
pin, we can control how fast or slow, reverse or forward mode the linear actuator should travel. Since 
the valve manifold we use has four single valves inside it, we tried to replicate with four motors, naming 
them valve1, valve2, valve3 and valve4. The motor and valve driver have the same design of two 
connections into positive and negative rails of power supply, as we observe the black and red wires in 
the picture. These four valves will be turned on and off through four separate 8-pin CoolDrive One valve 
driver as represented in four green 8-pin headers. The input to pin 1 and pin 2 will be 12 V of power to 
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power the valve when on through pin 8 and 9. This power delivery is turned on and off through the 5 V 
digital signal from Arduino feeding into pin 5 of the valve driver. A more detailed schematic of the 
resistances and voltages at each step during this process can be seen in Figure 25.  
 
Figure 25 Fluidic control subsystem detailed schematic 
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4.4.4 Temperature Control  
4.4.4.1 Temperature Control System Architecture  
 
Figure 26 Prototype temperature control system architecture drawing 
 
Figure 27 Image of entire temperature control system 
Figure 26 presents a block diagram for the heat control system flow and Figure 27 shows the 
experimental setup of the temperature control system. As we can see, the MC33926 motor controller 
driver will receive Arduino command for how much power should be drawn from the power supply and 
fed into the Peltier TEC module. This amount of power in blue then flows into the Peltier TEC, triggering 
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the Peltier effect across the p-n junction and generating heat flow in red to the machined aluminum plate. 
The plate temperature will be reported back to the Arduino in order to readjust power magnitude so as 
to make the metal plate stays consistently near the desired assay temperature. The heat/cold flow in red 
on the other side will be absorbed through the heatsink and then blown away by air flow in green from a 
DC cooling fan. This method is to prevent change in temperature on the opposite site facing heatsink from 
disturbing heating process at aluminum plate.   
4.4.4.2 Temperature Control System Schematic 
 
Figure 28 Temperature Control System Schematic 
Similar to the previous shown schematics for fluidic control, the MC33926 Motor controller 
Arduino Shield is replaced with a MD03A Motor Driver since there is not a schematics library for MC33926 
version. As we can see on the motor driver board, the two ports in middle are connected to an 8 V battery 
to drive the Peltier TEC module through the two top terminals. Power magnitude and polarity are also 
controlled through Arduino commands. Additionally, the LM35 temperature sensor reports data through 
analog input pin 3 on the Arduino. Moreover, the DC cooling fan is controlled through a switch-like NPN 
transistor. When digital pin 31 writes a high signal to the middle terminal of NPN transistor, the cooling 
fan yellow negative terminal is connected to both ground and turn on. On the other site, if the digital 
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signal is low, the negative terminal is connected to the open circuit and no power can flow across the DC 
fan. The entire schematic for the temperature control system can be seen in Figure 28 and a more detailed 
schematic of the resistances and voltages at each junction can be seen below in Figure 29.  
 
Figure 29 Temperature control subsystem detailed schematic 
4.5 Pretotype Design 
The team’s client statement included creating both a prototype of the proof-of-concept device 
and a pretotype for the potential future product. A pretotype is a future concept describing the 
completed product as it could be in the future, upon completion of the project, with all goal product 
objectives met. The objectives for this device include that the device be automatable, multiplexed, time 
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efficient, cost efficient, scalable, regulation compliant, and used for autologous transplant of MSCs. The 
pretotype describes the ideal sub-sections of the device, consisting of a sample preparation area, 
reagent distribution system, temperature control regions, proper reagent storage, waste storage and 
removal system, and finally the assay plate itself where the assays will be performed. A SolidWorks 
mock-up of a potential design for this device can be seen in Figure 33 below. 
    
Figure 30 SolidWorks drawing of potential assay device (left) and potential assay device integrated into a lab bench setting 
(right) 
In this device, the cell sample to be tested would be pipetted into the designated reservoir in 
the sample preparation section. After pipetting, the compartment door would be closed using the 
“open/close” button on the device. The sample preparation section would contain a centrifuging and 
supernatant collection region and a cell lysis solution creation region in order to transfer the correct cell 
solution into the assay plate. This section will also be capable of creating standard dilutions or control 
solutions as needed for the assays. After sample preparation, the reagents will be transferred 
automatically from the sample preparation section to the assay completion system, using fluid controls 
that are completely contained within the unit. This section would be temperature controlled as per the 
assay requirements. The assay reagents are stored in temperature regulated reservoirs that adhere to 
the appropriate storage conditions. The system is also equipped with pumping and valve controls to 
transfer the reagents from the storage reservoirs to the assay plate with controlled flowrate and 
pressure. A waste region would also be contained in the device for the collection of any waste or 
residual reagents from the assay. The assays would be completed on a 96-well disposable plate, which 
will be pre-coated with the necessary surface chemistry required to run each assay. The plate has a 
separate section for each assay to be completed, namely BSA, mycoplasma, endotoxin and trypsin. 
Finally, the device would be equipped with a user-interface screen indicating the conditions within the 
device, including pressure and temperature, and the status of the assay completion. Upon completion 
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the device will indicate “complete” on the UI screen. The assay plate would be removed and placed in a 
standard absorbance microplate reader to obtain the results.  
The team also created a potential brochure (Appendix A) for advertising the device and its 
advantages over the current methods of quality control. There would many advantages of using the 
device by automating the device to multiplex these four assays simultaneously. Multiplexing the assays 
would largely reduce the labor, time, and cost involved during the assay process, especially since each 
cell sample for autologous transplant must be tested separately. The device would be affordable as well 
as easy to use and conveniently sized in order to fit on a standard lab bench. By automating the assays, 
the results will have increased accuracy and will greatly reduce the chance of errors and false results 
from the tests because human error would be almost entirely removed. The device would be very 
efficient and would not require any additional equipment.  
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5 Design Verification 
This chapter will discuss the experiments that the team conducted to test various parts of the 
device to ensure functionality of each subsystem. These experiments were planned and conducted with 
proof-of-concept in mind and were designed to show that this design was feasible and can be pushed 
forward in the future. These experiments were created specifically for this project but in the future 
when the device has been refined further, the group would recommend adhering to standard methods 
of testing for this type of device, based on the engineering standards referenced in section 3.2.2. As a 
medical device, the system must meet these standards in order to be introduced onto the market and 
into testing laboratories in the future.  
5.1 Assay Experimentation 
5.1.1 Mycoplasma Baseline Assay Experiment 
During the assay experimentation process, the team decided that it would be necessary to run a 
baseline assay test for each of the chosen assays using the manufacturer’s procedure and standard 
laboratory equipment. There were no automated steps used in the baseline assay experiments and all 
fluid handling was completed by hand with standard pipettes. Temperature control was accomplished 
with a water bath and a standard incubator, as specified by the manufacturer instructions. The results 
from these baseline assays could later be used as a comparison against the results of the assay run using 
the system to show the system’s level of effectiveness. These assays were run solely with the controls 
included with the kits because no cells were used in the duration of the project.  
5.1.1.1 Initial Mycoplasma Assay Run 
The team first ran the R&D Systems Mycoprobe Mycoplasma Detection assay using the 
manufacturer insert procedure (Appendix B) as well as standard methods and lab equipment for volume 
dispensing, incubation, and transfer. The kit that was used for this baseline test was already available in 
the lab, as a leftover from the previous TRT that had already been completed. The team used this kit 
because of its availability. A new kit was ordered from the manufacturer but had not yet arrived at that 
time.  
During this experiment, the team encountered a number of setbacks which led to inconclusive 
and unusable results. The experimental plan called for three wells of the positive control and three wells 
of the negative control. However, there was only enough positive control left in the kit for one full well 
to be run. Additionally, this assay kit had been stored for about six months in the lab, which was three 
months longer than the manufacturer insert claimed the kit would be usable for. The assay was run as 
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described despite these problems in order to become more familiar with the process for the next 
experiment.  
After completion of the assay, the wells were read in a standard microplate reader at 450nm 
wavelength and a color change should have occurred but was not visible, as can be seen in Figure 31 
below. A successful assay run would have resulted in the positive control wells turning a dark red color 
and the negative control wells remaining clear. Use of the microplate reader yields the optical density 
(OD) of each well, which was required to be above or below a certain threshold, as described by the 
manufacturer, to be deemed acceptable. At the completion of this experiment, the team decided that 
the data was not accurate enough to be used as a baseline and that the experiment would need to be 
run again.  
Table 4 Manufacturer included OD result comparison (left) Experimental OD and results (right) 
   
  
 
 
Figure 31 Mycoplasma Assay Initial Run Result Wells.  
Right two wells: positive control; left three wells: negative control  
 
 
 
 
  
Experimental Condition Optical Density Result 
Positive Control 0.0106 Negative 
Positive Control 0.00934 Negative 
Negative Control 0.0102 Negative 
Negative Control 0.00648 Negative 
Negative Control 0.00934 Negative 
OD Values  Result 
<0.05 Mycoplasma Negative 
0.05-0.1 Inconclusive 
>0.1 Mycoplasma Positive 
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5.1.1.2 Secondary Mycoplasma Assay Run 
In this experiment, the team used a new R&D Systems mycoplasma detection kit to ensure that 
the baseline data was accurate. The manufacturer insert was again followed and standard laboratory 
procedures were used to conduct the assay. At the conclusion of the experiment, the wells were again 
read in a microplate reader to determine the optical densities of the solutions. The assay was successful 
during this experiment and the positive and negative controls reacted as expected with the appropriate 
optical densities present, as seen in Figure 32 below.  
It is important to note that for both baseline mycoplasma assay runs, there was a slight 
misinterpretation of data due to human error. The plates are meant to be read at 490nm and then again 
at 600nm, with the second value being subtracted from the first value to get the final optical density of 
the value. This difference is meant to account for the optical imperfections in the well plate and is 
recommended by the manufacturer. Upon further inquiry with the manufacturer after this mistake was 
made, the team decided that these results were acceptable because had the difference been taken, the 
negative controls would have been in the correct range to represent a negative value. This decision was 
also necessary because of the time and material constraints that the team was under.  
Table 5 Manufacturer included O.D. result comparison (left) Experimental O.D. and results 
   
 
 
 
 
 
Figure 32 Mycoplasma Assay Seconday Run Result Wells. 
 Left three wells: positive control; right three wells: negative control 
Experimental Condition Optical Density Result 
Positive Control 2.05 Positive 
Positive Control 2.02 Positive 
Positive Control 2.16 Positive 
Negative Control 
0.161 
Incon-
clusive 
Negative Control 
0.1 
Incon-
clusive 
Negative Control 
0.113 
Incon-
clusive 
O.D. Values  Result 
<0.05 Mycoplasma Negative 
0.05-0.1 Inconclusive 
>0.1 Mycoplasma Positive 
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5.1.2 BSA Baseline Assay Experiment 
The team also ran a baseline assay experiment for the BSA assay to have results to compare to 
once the project was successfully completed. The team used the MyBioSource BSA Detection Kit in this 
experiment and the manufacturer insert instructions (Appendix C) were followed accordingly. This 
assay, different than the previous, used a standard dilution curve as a control. The experiment was run 
only with the standard curve and again with no cells.  
5.1.2.1 Initial BSA Assay Run 
The first assay run was conducted with a previously used kit obtained from the TRT prior work 
and therefore again presented potential errors because of the length of storage time. Despite this 
excess of time, the experiment was conducted as planned with the standard BSA dilution curve run in 
duplicate. The assay kit included a graph of an expected BSA standard curve that could be used as a 
reference for the curve created from the experimental assay and can be seen in green in Figure 33. 
At the completion of this experiment, the wells were read at 490nm wavelength and the results 
were analyzed according to the manufacturer, graphing the optical density versus the log of BSA 
concentration. The resulting standard curves, shown compared to the manufacturer example in Figure 
34 below, were intended to have a gradient from virtually clear to dark yellow but this result was not 
present. The standard curves were both inaccurate and could not be considered as appropriate baseline 
data to compare to in the future. Therefore, the team again decided to rerun the experiment to achieve 
better results.  
 
Figure 33 Initial BSA Assay Standard Dilution Curve compare to manufacturer example 
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Figure 34 Initial BSA assay result wells. Descending concentration from  
left-most well (30,000 ng/mL) to right-most well (0ng/mL) 
5.1.2.2 Secondary BSA Assay Run 
The second iteration of the BSA detection assay was successful and able to be used as baseline 
data for future comparison. The team used a new MyBioSource BSA detection kit for this experiment 
and followed standard laboratory procedures and the manufacturer instructions. At the completion of 
the assay, a decided gradient could be seen in the wells. However, there was a limited amount of the 
dilution reagent which only allowed for one standard curve to be run rather than two. The absorbance 
readings were again analyzed and graphed and the results can be seen in Figure 35 below. The wells at 
the conclusion of the experiment can also be seen in Figure 39.  
          
Figure 35 Baseline BSA Assay Standard Dilution Curve (left) and BSA resultant wells (right) with concentration descending 
from top right well (30,000 ng/mL) to bottom right (0ng/mL) 
5.2 Fluidic Control Experimentation 
5.2.1 Syringe Pump Calibration Curve Determination Experiment 
5.2.1.1 Purpose  
The purpose of this experiment was to find correlation between linear actuator distance and 
volume of water dispensed by the automated syringe pump. Using this correlation, a calibration curve 
could be generated that related this distance and volume and integrated into the Arduino code. After 
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integrating this calibration into the Arduino code, ideally the system would be much more accurate in 
dispensing the desired amount of volume.  
5.2.1.2 Experimental Procedure  
This experiment was performed using the pre-existing syringe pump assembly consisting of a 
1mL glass syringe and linear actuator in a machined aluminum frame. The assembly was connected to a 
programmed Arduino Uno controller board to initiate and terminate movement of the linear actuator. 
The Arduino code was programmed to prompt the user for a position value that the linear actuator 
would then travel to.  
 The first step in this experiment was to determine the maximum volume that the syringe could 
intake. Though it was a 1 mL syringe, the aluminum frame restricted full movement of the syringe so it 
was unable to reach capacity. The group achieved this by taking water into the system to the linear 
actuator’s limit and measuring the mass difference of the reservoir the water was taken from. The 
average intake was measured at 768 µL.  
 To measure the calibration between linear actuator distance and volume output the team filled the 
syringe to capacity, input randomly chosen linear actuator positions, and measured the output volume 
of fluid dispensed. A total of 12 linear actuator positions were tested and the entire experiment was 
repeated three times with these volumes to ensure accurate data. A full description of the experimental 
procedure can be found in Appendix D. 
5.2.1.3 Experimental Results and Analysis   
 At the conclusion of the experiment, the group transferred the collected data to Excel for 
analysis. To create the calibration curve, the distance travelled by the linear actuator was plotted against 
the volume output at that position. To achieve the most accurate curve, data points from all three 
experimental iterations were included in this plot but major outliers were removed. These outliers were 
removed because they were most likely due to human error and did not reflect on the effectiveness of 
the system. The graph in Figure 36 below shows the calibration curve between the linear actuator 
distance and the volume dispensed with outliers removed. The full data set and graph including outliers 
can be seen in Appendix D. The calibration curve created in this experiment was then integrated into the 
Arduino code so the team could input a value into the code and know with relative certainty what 
volume would be dispensed.  
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Figure 36 Graph of output volume vs. linear actuator distance data from all experimental iterations without outliers (left). 
Generated calibration curve from all iteration data with outliers removed (right). 
5.2.2 Syringe Pump with Manifold: Dead Volumes Experiment 
5.2.2.1 Purpose  
The purpose of this experiment was to empirically determine the volume lost in the solenoid 
valve manifold when various volumes of fluid were dispensed by the syringe pump system. This 
information would be used to factor in to the volume entered into the Arduino code to be dispensed by 
the system. 
5.2.2.2 Experimental Procedure 
The procedure for this experiment was similar to that of the previous experiment, with the main 
difference being the integration of the solenoid valve manifold into the syringe pump system. The 
system was filled to capacity and randomly chosen output volumes were entered into the Arduino code. 
The subsequent output volume was compared to the goal output volume to create another curve for 
the system with the integrated manifold. This experiment was performed with the 12 chosen volumes 
from the previous experiment to output and the entire experiment was performed three times. A fully 
detailed description of the experimental procedure can be found in Appendix E. 
5.2.2.3 Experimental Results and Analysis 
 The data was collected and analyzed in Excel. The goal volume output is compared 
graphically to the actual volume output of the system. This curve was then compared to the previously 
created calibration curve to identify any discrepancies or offsets. This comparison can be seen in Figure 
37. The team observed that the offset between the curve created without the manifold and the curve 
created with the manifold was not uniform. It was initially hypothesized that the valve manifold would 
have a constant volume lost within it. However, the data showed that the amount of volume lost in the 
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system slightly increased as the volumes dispensed increased. The full data set from this experiment can 
be found in Appendix E.  
 
Figure 37 Volume output comparison between system with and without manifold 
5.2.3 Syringe Pump with Manifold: Intake Accuracies Experiment 
5.2.3.1 Purpose  
The goal of this experiment was to determine the accuracy of the fluid intake of the syringe 
pump and valve manifold system. This information would show the team if the system was capable of 
taking in the goal amount of volume or if there was volume not taken in by the system.  
5.2.3.2 Experimental Procedure 
To perform this experiment, the team used the syringe pump system with the integrated valve 
manifold as described in previous sections. A fluid reservoir was then filled with water and weighed. A 
range of randomly selected volumes between 0 and 700 µL were chosen as intake volumes and entered 
into the Arduino code. After the syringe pump, which began fully empty, had taken in the entered 
volume of fluid, the mass difference of the reservoir was measured to determine the actual intake of the 
system. 12 volumes were tested and the experiment was repeated three times. A fully detailed 
description of the experimental procedure can be found in Appendix F. 
5.2.3.3 Experimental Results and Analysis  
Once the data was collected, it was transferred to Excel for analysis. The team compared the 
goal volume input values to the actual volume taken in by the system, as seen in Figure 42. However, 
this graph is not an accurate representation of the experimental results because its relatively linear 
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relationship is misleading. The team then plotted the goal input volumes against the change in volume 
that corresponded to each data point. This graph signified the difference between the goal intake 
volume and the actual intake volume to show how much volume was not taken in by the system, as 
seen in Figure 38. This graph shows that the intake loss was not uniform but was consistent over the 
three iterations of the experiment. These results were disappointing as there was such a large difference 
between the goal intake and actual intake of the system. The full data set from this experiment can be 
found in Appendix F. 
  
Figure 38 Results of system intake experiment: goal intake vs. actual intake (left). Change in intake volume vs. goal volume 
intake (right) 
5.2.4 Syringe Pump with Manifold and Air Pump: Output Volume Loss Experiment 
5.2.4.1 Purpose  
The purpose of this experiment was to determine the effectiveness of an attached air pump 
used to flush the valve manifold of volumes left behind after dispensing. If seen as effective, this 
attached air pump could be used to more accurately dispense volumes and ensure that all fluid was 
removed from the manifold.  
5.2.4.2 Experimental Procedure  
In this experiment, an air pump was integrated into the system between the valve manifold and 
syringe pump. The procedure for this experiment was similar to previously described experiments, 
beginning with a full syringe and dispensing to a range of randomly chosen volume values. After 
dispensing the volume of fluid, as in previous experiments, the air pump was turned on for 1-2 seconds 
to allow all residual fluids to be flushed from the system and into the collection reservoir. The reservoir 
was then weighed to identify the mass difference and final output volume from the system. This 
experiment consisted of 12 volume data points and the entire experiment was performed three times. A 
detailed description of the procedure can be found in Appendix G.   
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5.2.4.3 Experimental Results and Analysis  
Upon completion of the experiment, the data was collected and transferred to Excel for analysis. 
Upon further analysis of the data, it was seen that the air pump did assist with increasing the amount of 
volume that was dispensed from the system. When comparing the amount of volume lost in the system 
when using the air pump to the amount of volumes lost in the system when the air pump was not 
integrated, as seen in Figure 39 below, the group saw that the volumes lost became less varied upon 
integration of the pump. However, the team decided against integrating the pump into the system 
because of the excess amount of tubing required to attach the air pump. Because the previous intake 
experiment proved to be rather unsuccessful, the team did not want to integrate any more unnecessary 
tubing that could decrease the intake accuracy even more. Therefore, it was decided to implement the a 
vacuum air pump instead, only as needed, in order to fully flush out the system between reagent 
additions. Therefore, it would not introduce additional tubing during intake but could still assist with 
ridding the system of the left behind volumes.  
  
Figure 39 Distribution of volume lost with air pump integration (left) and distribution of volume lost with no air pump (right) 
5.2.5 Cross Contamination Experiment 
5.2.5.1 Purpose  
One of the final experiments that the team conducted was a qualitative cross contamination 
test to determine if the system was being fully cleared out by the integrated vacuum. This was necessary 
in order to lessen the chance of mixing between the reagents and compromising of the assay.  
5.2.5.2 Experimental Procedure 
During this experiment, the team used yellow dyed water to fully fill the system and then 
dispense all volume into a 96-well plate, as can be seen in the bottom row of Figure 40 below. This 
water was not contaminated because it was the first color through the system. We then disconnected 
the manifold from the syringe pump and fully vacuumed it out, opening all valves and leaving the 
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vacuum on until no liquid was seen leaving the manifold. The syringe pump itself, still separate from the 
manifold was filled and emptied with uncolored water 3 times to ensure that any residual color was 
eradicated. The system was then filled with red colored water and the emptying process was repeated. 
Finally, yellow water was taken in and pumped out of the system again and the resultant wells were 
observed for any color change that might have occurred from residual red colored water. We repeated 
the whole process again with yellow colored water as the base again but then followed with green 
colored water as the secondary color.  
5.2.5.3 Experimental Results and Analysis  
The team saw that the residual volume removal did not fully clear out the system as we had 
hoped. Even after extensive vacuuming of the valve manifold, we saw that both red and green colored 
water affected the yellow colored water that followed it. However, the concentration of the 
contaminated color did lessen in later wells but the color was still present. The results from this 
experiment can be seen in Figure 40, where the top/left wells were the result of the green colored water 
contamination, the middle wells were the result of the red colored water contamination, and the 
right/bottom wells are the result of no contamination for comparison. This was a qualitative experiment 
due to lack of time. However, though the results were only obtained visually, the team believed the 
outcome was still helpful for the project.  
   
Figure 40 Top view of contaminated wells (left). Side view of contaminated wells (right) 
5.2.6 BSA Assay Run: Water Trial Experiment 
5.2.6.1 Purpose 
The purpose of this experiment was to determine if the system was able to correctly intake and 
dispense the specific volumes needed to run the BSA detection assay. This experiment was run as a 
mock assay trial using water instead of reagents to ensure that materials did not go to waste if there 
was a flaw in the system. For this experiment, the system that was used was our final prototype system, 
containing the syringe pump, solenoid valve manifold, and detachable vacuum.  
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5.2.6.2 Experimental Procedure 
To complete this experiment, the team followed the MyBioSource kit insert instructions to 
determine what volumes would be necessary for the BSA assay. The system was then used to intake and 
output water in the same way that would be used in the actual assay run, namely using the automated 
pumping system to intake and output fluid but with manual control over tubing to ensure accuracy in 
delivering the fluid. The desired intake volume was entered into the Arduino code and after the intake 
was completed, the system would be returned to position zero to empty the contents into the desired 
well. The intake and output was performed on four volumes dispensing into six wells and the entire 
experiment was completed three times. A full description of this experimental procedure and a table of 
the volumes used in this experiment can be found in Appendix H.  
5.2.6.3 Experimental Results and Analysis  
At the completion of the experiment, the team saw that the system was consistently dispensing 
less volume than had been requested. However, a relatively consistent amount of water was lost at each 
of these volumes, as seen in Figure 41 below, which allowed the team to be able to account for the 
volume loss at each point. Based on the data collected, the team decided to integrate a volume buffer 
into the volume value that was entered into the Arduino software. After averaging the output losses and 
differences in volume intake at volume point, the volume buffer was determined to be 15 µL. The full 
data set can be found in Appendix H. 
 
Figure 41 Distribution of volumes requested vs. actual volume output for four volumes 
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5.3 Temperature Control Experimentation 
5.3.1 Heating from Room Temperature to 65° C Experiment  
5.3.1.1 Purpose 
The purpose of this experiment was to determine the time it took to heat the control system 
from 24 °C to the maximum incubation temperature, 65 °C, and vice versa. It was also necessary to 
determine if there was a major difference in heating times when the system was connected to an 80x80 
mm heatsink or a 60x60 mm heat sink.  
5.3.1.2 Experimental Procedure  
To complete this experiment, the temperature control system was set up with a temperature 
sensor attached to the aluminum assay strip well platform for monitoring its surface temperature. The 
Peltier module was connected to the aluminum plate on the side that would be generating heat and to a 
heat sink on the other, which would be diffusing heat and cooling. Either side of the Peltier module can 
be used to heat or cool depending on the voltage and polarity applied to it. There were two size options 
for the heat sink: 80x80 mm and 60x60 mm and the system was tested with both in order to identify any 
major differences between the two. In addition, other specifications such as block mass, block area, 
Peltier module area, and polystyrene well was kept the same as discussed in the modelling section.  
This experiment was completed by controlling the system with a motor driver board and an 
Arduino Mega microcontroller board. Energy was delivered to the Peltier module to heat up the 
aluminum plate by controlling the “speed” parameter of motor driver board. This speed is the output of 
the PID control system, which is implemented inside the Arduino. The input of the PID control loop is the 
temperature data from the temperature sensor. In general, the Arduino PID control loop continuously 
keeps track of how far the plate is from the goal temperature. For example, to go from RT (~24 °C) to 65 
°C, the PID control will tell the motor controller to allow full current draw from the Peltier at 8 V. As the 
aluminum gets closer to the desired temperature, the current draw to the Peltier module decreases 
until the temperature is reached.   
It is important to note that this test was carried out by filling 75% volume of each well with 
water. Each well volume is 360 µL maximum. The well strip was placed in the aluminum block for 
heating and was open to room temperature air with a temperature of about 24 °C. The temperature 
sensor LM35 was used to measure the metal block temperature, data of which was then recorded into 
Arduino serial monitor. For parallel monitoring, we dipped a Fluke thermocouple into the water of one 
well and double checked that when the metal block stabilizes at the assay temperature, the water 
should be at the same temperature too.   
77 
 
5.3.1.3 Experimental Results and Analysis 
The data collected from the Arduino during the experiment showed that the temperature 
control system reached its goal temperature and remained there after about four minutes. The goal for 
the system was that it should be able to heat to the desired temperature in less than five minutes.  
 
Figure 42 Heating from room temperature (24 °C) to 65 °C with 80 x 80 mm attached heat sink 
  
 
Figure 43 Heating from room temperature (24 °C) to 65 °C with 60 x 60 mm attached heat sink 
As we can see from Figure 42 and Figure 43 above, the heating characteristics of both graphs are 
similar. From room temperature of 25 °C heating to 55 °C, we have a nearly linear increment. This is due 
to the PID controller seeing that aluminum block is still far from the desired heat goal so it allows full 
current draw from Peltier TEC module. From 55 °C to 60 °C, the PID starts decreasing current draw 
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allowance, which results in a non-linear curve of temperature that stabilizes upon reaching goal 
temperature. In general, the heat system can go from room temperature to 65 °C in less than five 
minutes, which meets the temperature transition goal.  
Because the heating behavior of system with two different heat sinks, 60x60 mm and 80x80 
mm, is very similar, we can assume that the size of the heatsink does not affect significantly the heating 
performance of the system. Therefore, to determine which heatsink to use, more experiments needed 
to be conducted. 
5.3.2 Cooling from 65 °C to Room Temperature (24 °C) Experiment 
5.3.2.1 Purpose 
The purpose of this experiment was to ensure that the system was capable of cooling the 
aluminum block from the highest incubation temperature, 65 °C, to 24 °C within the specified amount of 
time, five minutes. It also provided more data on which heat sink was a better option for the system.  
5.3.2.2 Experimental Procedure 
After reaching 60 °C, we turned off the power delivered to Peltier module and turned on the 
cooling fan. However, as mentioned earlier, one of the problem with this is that Peltier’s job is to 
maintain a heat difference across two plates. For example, if the allowed temperature difference 
between the two surfaces is 70 °C and the hot side temperature is currently 30 °C, it allows the cold side 
to be -40 °C. However, this is not always true. Since the heating effect on cold side is significant that it 
will keep increasing the heat much faster than the cold side, the cold side need to go back to -20 °C, -10 
°C, 0 °C and start going above 0 °C again. Even though we already implemented a heatsink and cooling 
fan for this problem it does not go away entirely. As a result, the longer we reverse energy delivered, the 
more heat we may get later instead of cold, which can slow down our cooling process. Therefore, 
triggering this reverse action at lower temperature definitely saves more power usage than at 60 °C. As 
a result, we decided to only turn off the Peltier module and use DC cooling fan for the first few minutes 
of cooling. We observed that with this approach, the cooling process still dropped fast until reaching 29 
°C. At 29 °C, since the temperature is close to room temperature, the cooling process slows down. At 
that point, we then start reversing the energy delivered to Peltier module, while the DC cooling fan 
remains on the whole time.  
5.3.2.3 Experimental Results and Analysis  
Below is the experimental data of this method for the two sizes of available heatsinks. As we can 
see from Figure 44, the small heatsink can get the system to cool down faster. Take a point at 200 
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seconds, the small heatsink decrease the system to 27 °C while at 200 seconds, the larger heatsink cools 
the system down to 30 °C only. From this result, we chose the 60x60 mm heatsink as the better option.  
  
Figure 44 Cooling from 65 °C to room temperature with 80x80 mm heat sink (left) and system cool from 65 °C to room 
temperature with 60x60 mm heat sink (right) 
5.3.3 Temperature Control System Cooling Experiment   
After doing testing on all options that we have: aluminum versus copper, aluminum sheet versus 
machined aluminum block, and 60 x 60 mm versus 80 x 80 mm heatsink, we finalized the components in 
each of the conclusions discussed in the Final Design section. We also knew that the system can remain 
stable around 65 °C, which is the max temperature needed for the assays Therefore, the team 
performed an experiment with this final design to test if it can stay stable at room temperature after 
cooling down from 65 °C.  
 
Figure 45 Cooling stability graph of cooling the system from 60 °C to 24 °C 
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As we can see from Figure 45, the heat block went down from 55 °C to room temperature of 24 °C 
and stayed there from time 400 seconds to time 690 seconds, which showed that the system was 
capable of keeping the metal block stable at room temperature.  
It was important to note that in these experiments, we had 60 °C instead of 65 °C because of the 
offset between the temperature sensor feeding data to the Arduino versus the true temperature of 
metal block. The true temperature was measured through a more sensitive sensor, which was a Fluke 
thermistor. By placing both sensor in the same location, we observed that when the Fluke thermistor 
claims 65 °C, the LM35 sensor sees 60 °C. Moreover, some of the cooling graphs start from 55 °C instead 
of 60 °C. This change was because when we turned off the power supply and changed the desired 
temperature in the Arduino to room temperature, it took around five seconds for the data collecting 
monitor to start recording. These 5 seconds resulted in the previous 5 °C drop from 60 °C that we cannot 
monitor.  
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6 Design Validation 
Device validation is necessary to show that the design created is effective and meets the goals 
that were originally set out at the outset of the project. Typically, validation for a medical device would 
take place in a clinical setting where it would be put to use as a replacement for the system being 
improved. However, for this project, the designed device was not able to be used in a clinical setting 
because the final goal was proof-of-concept rather than immediate clinical application. Therefore, the 
team validated the system as much as possible by showing that the system was capable of accurately 
running the assays that the final device would automatically run in a clinical setting. Running these 
assays with the system shows that the device is capable of the fluid and temperature control necessary 
for the assays and therefore proves that this idea is feasible and can be moved forward in the future.  
6.1 Prototype Validation: BSA Assay Run with System 
The first assay run to show validation of the designed system was the BSA detection assay. The 
manufacturer procedure was followed using the system instead of typical laboratory equipment, 
including pipettes and incubators. During this experiment, the team ran the included BSA standard 
dilution curve to show completion of the assay. No cell solution was tested in the experiment, as the 
main goal was only proof-of-concept. The standard dilution curve was created by hand, using standard 
laboratory tools. We chose this method of creating the standard curve because in the future device, a 
separate sample preparation station will be responsible for this task. Because we were only 
demonstrating proof-of-concept for the reagent distribution system, the team decided that the curve 
should be created by hand to ensure that it was as accurate as possible before the system was used. 
Once the dilutions were created, the subsequent steps of the assay were completed in duplicate using 
the system with manual control of tubing as necessary. This device is only semi-automated and 
therefore all fluidic output and intake was automated but it was necessary to move the intake/output 
tubes into the subsequent wells and reagent reservoirs by hand. This step would be automated in the 
future but the project was unable to reach that stage during the seven week time period.  
Once the assay was successfully completed, the plate was read in an absorbance plate reader at 
450 nm and the values were plotted against the log of the BSA concentration in each well, as seen in 
Figure 46 below and the full data set can be found in Appendix I. The resulting curves showed a 
descending concentration, as necessary, but offset from the baseline assay run data. Iteration 1 was 
significantly more uniform and more accurately showed the desired results. The curve representing 
Iteration 2 was offset and unpredictable, showing that the device had the ability to correctly control 
fluids dispensed but was not consistent in doing so. The team believed the explanation for the offset of 
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the curves was due to the system consistently dispensing about 15 µL more than required. This volume 
offset would also increase the concentration of the reagents added to the various wells, which would 
cause the entire curve to be slightly offset. However, for the sake of consistency, the group did not 
modify the system to account for this 15 µL offset during this or the next experiment.  
 
Figure 46 Comparison of baseline assay test results and system assay test results 
6.2 Prototype Validation: Mycoplasma Assay Run with System  
The team also completed the mycoplasma detection assay using the system instead of the usual 
laboratory tools. To complete this assay, again no cell solutions were used and only the 
positive/negative controls were run to show proof-of-concept. The manufacturer kit instructions were 
closely followed. Three wells of each positive and negative control were run and the results were 
compared to those of the baseline mycoplasma assay results. The results of the system assay run 
showed that the 15 µL volume offset again increased the concentration of the wells. The colorimetric 
differences between the baseline assay wells and the system assay wells can be seen in Figure 47 below. 
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Figure 47 Comparison of baseline mycoplasma assay results (top) to system mycoplasma assay results (bottom). Positive 
controls indicated by darker red color: left wells. Negative controls indicated by transparent color: right wells. 
The resulting assay wells were read in an absorbance plate reader at both 490nm and 600nm 
and this data set can be found in Appendix J. The optical densities measured at 600nm were then 
subtracted from the readings at 490nm to account for the optical imperfections in the assay plate, as 
instructed by the assay manufacturer. These final optical densities were then compared to a table 
provided by the manufacturer that specified what optical densities corresponded to a positive, negative, 
or inconclusive result. The results and the manufacturer information can be seen in Table 5 below.  
Table 6 Manufacturer specifications for assay results (left).   
Optical density comparison between baseline and system assay results (right) 
   
  
 
 
 
 
 
  
Experimental Condition Average Optical 
Density (490 nm 
–600 nm) 
Result 
Baseline Assay Run: 
 Positive Control 
1.14 
Positive 
Baseline Assay Run: 
Negative Control 
-0.127 
Negative 
System Assay Run: 
Positive Control 
3.02 
Positive  
System Assay Run: 
Negative Control 
0.269 
Positive 
O.D. Values 
(490 nm – 
600 nm)  
Result 
<0.05 Mycoplasma Positive 
0.05-0.1 Inconclusive 
>0.1 Mycoplasma Positive 
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7 Discussion  
The results of this project were positive overall and showed that the device created is a 
legitimate first step in designing a fully automated, multiplexed assay machine but would need 
significant improvement in the future. Because the team’s main goal was basic proof-of-concept, the 
created prototype reached this goal but could not meet all expectations because of the limited span of 
time in which the project was completed. The biggest obstacle that the team faced was the time 
constraint of the seven week onsite portion of the project. Because of this short span of time in which to 
complete the project, it was vital that the team waste no time and use as many available resources as 
possible. As such, it was necessary to use components that were not ideal but were necessary because 
of their immediate availability. If the project were to be continued in the future, the ideas and 
knowledge gained by this proof-of-concept device could be applied to better, more appropriate 
components to make the device significantly more reliable and successful.  
Another important aspect of this project was the level of automation of the system. Since it was 
designed to be a proof-of-concept device, the system was only semi-automated and did require a high 
level of manual control, including tubing control and Arduino code prompts, in order to perform 
successfully. However, had time allowed, the team is confident that the system would be able to 
become significantly more automated.  
Additionally, the long term goal for this device is to greatly reduce time and labor costs because 
of the automated nature of the device. At this stage of project development and because the device was 
only semi-automated, we were not able to show a reduction of time spent on completing the assays and 
therefore this area of concern could be improved in the future. However, if work on this project 
continues, the group is confident that a large reduction in manual involvement time would occur. This 
time reduction would also greatly lessen labor costs because a laboratory technician’s time could be 
spent working on other areas and not focusing solely on completing the QC tests.  
7.1 Fluidic Control System Discussion 
 The fluidics control portion of the device was only partially successful and therefore would 
require significant improvement in the future when this project is developed further. The team’s 
extensive testing showed that the system was capable of controlling the volumes of fluids necessary to 
run the assays but was often inconsistent in doing so accurately. Therefore, different components would 
have to be integrated into the system in the future in order to increase the accuracy and consistency of 
the device.  
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 One of the main issues with this design was the solenoid valve manifold, used to intake volumes 
into the syringe pump and output them into a specific well. When the solenoid valve manifold was 
integrated into the system, intake and output both became more difficult because of the tortuous inner 
pathway of the manifold. The design of the manifold was such that the internal path was a zigzag 
between the valve ports, which led to extensive volume loss and inconsistencies with the 
measurements. The manifold was particularly problematic in regards to volume intake into the system. 
Looking at the experimental results, the team saw up to about a 30% volume loss of the volumes taken 
into the system. A potential reason for these inaccuracies is that the syringe pump was not large enough 
or powerful enough to generate enough of a vacuum to overcome the tortuous manifold pathway and 
bring the desired volume into the system. This discrepancy between goal and actual intake and output 
would not be acceptable in a final design and therefore would have to be addressed.  
Additionally, the valve manifold greatly increased the risk of cross contamination because of the 
number of places in which fluids could remain, even after pumping and vacuuming out the system. It is 
crucial to the success of the assays that preemptive reagent mixing is very limited or lacking entirely. The 
system was still able to complete the assays relatively successfully despite this problem, but it would 
definitely need to be addressed in future iterations of the design.  
The system also had significant difficulty accurately dispensing smaller volumes of fluid. Because 
of the length of the internal manifold pathway, moving from one valve to another often required a 
higher volume of fluid than was supposed to be dispensed. To address this problem, the system was 
filled with the reagent of choice and then the smaller volumes were pumped out after a number of 
“blank” volumes were dispensed. In an ideal system, this internal loss could be accounted for accurately 
in order to not waste reagents. Since the team was so limited by the time constraints of the project, this 
problem was not a high priority to address as long as the system could be manipulated to work 
correctly.  
7.2 Temperature Control System Discussion 
The temperature control portion of the device remained very successful throughout the duration 
of the project. The integration of the Peltier heating modules greatly increased speed and efficiency of 
both heating and cooling of the system and allowed for greater control over the temperatures involved. 
The system acted as an appropriate replacement for the typical incubator or water bath for heating of 
the assay plates. It was able to reach necessary temperature, whether by heating or cooling, within five 
minutes, meeting the goal the team had put in place.  
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7.3 Potential Project Impacts 
This section discusses the potential impacts our project could have on certain aspects of society. 
These considerations are necessary to ensure that this project will be beneficial in all areas.   
7.3.1 Economics 
This device would ideally have a positive impact on the economics of the medical device 
industry. It would lead to collaborations between assay manufacturers and the device manufacturer. 
Additionally, cost of quality control would greatly decrease because of the limited minimal involvement 
needed to use this equipment. Therefore, the laboratories in which it was used would save expenses on 
quality control that could be implemented elsewhere, giving business to more companies and positively 
impacting this field.  
7.3.2 Environmental Impact 
This device will have a positive environmental impact because of the reduction of disposable 
pieces used when the device is fully automated and functional. Because there is a reduction of human 
error, there will be less waste of any disposable pieces used by the machine. Additionally, the device will 
be mostly made up of reusable parts that will not be disposed of after every use, which also increases its 
level of positive environmental impact. 
7.3.3 Societal Influence 
If stem cell therapy becomes the norm in the future, then this device would have the capacity to 
have a very positive societal influence by increasing the safety and reliability of this method of 
treatment.  
7.3.4 Political Ramifications 
Political ramifications would be a minor issue for this device. There is little about this device that 
would cause it to cause any political ramifications because of its generally scientific and non-
controversial applications. One potential concern that could be raised is that the automatic nature of 
this device could remove jobs for those who do these tests manually currently. However, with the 
introduction of this device, those employees would be able to focus on increasing throughput of cell 
quality control in the lab and would be able to expand their field of interest. 
7.3.5 Ethical Concerns 
This device does not have any major associated ethical concerns. Whenever this device would 
be used, it would be with the direct consent of the patient whose cells were being cultured and 
transplanted. A potential ethical concern for this device is if it was expanded to the quality control of 
embryonic stem cells or a similar type of currently controversial cell type. However, the device itself 
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would only be acting as a method of QC and therefore should not be associated with the ethical 
concerns of the cells themselves.  
7.3.6 Health and Safety Issues 
Health and safety were the main concerns of this project because of the effects these cells can 
have on the patients they are reintroduced into. The goal of this device was to decrease human error 
and increase reproducibility to ensure that the cells were healthy and acceptable to be used as a 
treatment. If the cells have a false negative result, the patient’s safety can be at risk because of the 
effects these contaminants can have in an in vivo environment. Therefore, with the reduction of human 
error, this device will help to decrease the number of false negative results and better assure the 
usability of the stem cells for transplant.  
7.3.7 Manufacturability 
Because this device will be utilizing a number of currently existing technologies and subsystems 
combined into one device, manufacturability should be a minor concern. Because many pieces of the 
device are already manufactured separately, it would be relatively simple to assemble these parts into 
the final device.  
7.3.8 Sustainability  
The system would be made up of reusable and durable parts that would allow for long-term use. 
The final device subsystems would ideally utilize materials that would not degrade over time with 
regular use. Because of the expensive nature of the device, it would be necessary that it be a one-time 
purchase for laboratories because of the likely high cost involved.  
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8 Conclusions and Recommendations 
The goal of this project was to create a semi-automated proof-of-concept device that could 
demonstrate the ability to control the fluidic and temperature environment requirements for specific 
biological assays to be run correctly. In the future, this project will hopefully be advanced to a fully 
automated, multiplexed device that is capable of running the four key quality control assays, to detect 
mycoplasma, trypsin, endotoxin, and BSA, with high quality, reproducible results.  
Overall, we were able to create a proof-of-concept prototype that was capable of controlling 
fluids and temperature in such a way that allowed for successful completion of these biological assays. 
The fluidic control system would be required to be improved in the future because it was only relatively 
consistent with taking in and dispensing fluids from the system into the assay plate. A more accurate 
and consistent pumping system would have to be implemented. There was minimal cross contamination 
in the system, though some was present. Additionally, the correct temperature environment was 
provided by the temperature control system and the system was able to heat from room temperature 
to a maximum of 65 °C in less than five minutes and remain stable at this temperature for as long as 
required. It was also able to cool back down to room temperature in the same amount of time. Using 
these systems along with some manual involvement, the mycoplasma and BSA detection assays were 
able to be completed with acceptable results using only the system.  
Though we completed the goals set out at the beginning of the project, there is still a large area 
for improvement in the future. In regards to the fluid control system, it would be beneficial for the 
device to have a much more capable and accurate pumping and valve separation system. One potential 
option would be to integrate a peristaltic pumping droplet mechanism system. This type of system could 
greatly increase the level of control over the volumes released and decrease the chance of volume 
offsets. Another potential replacement for the syringe pump is a network of pinch valves connected to 
T-valves, each corresponding to a specific and separate reagent. Using built up pressure in the system, 
opening one valve for a specific amount of time would release a known amount of volume into the 
system. This idea would again yield higher control and less chance for inaccuracies with the volumes 
dispensed.  
The temperature control system could also be advanced in the future by integrating a storage 
system with the proper environment for reagents, which require specific freezing or refrigeration 
conditions if they are intended to be contained in the device itself. The device is designed to be as self-
sufficient as possible so including the reagents in the system would be a beneficial addition to the 
device. 
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In the future, the system would also benefit from being much more automated than the current 
prototype device. Because of the time constraints of the project, it was higher priority for the team to 
ensure that the processes themselves were working rather than concentrating on automating a system 
that might not be functional. Therefore, now that the system has proved functional, it would be 
beneficial to integrate additional steps into the Arduino code to greatly lessen the amount of manual 
involvement necessary for the system to function correctly.  
In conclusion, our MQP was relatively successful in showing proof-of-concept of the created 
system. However, there were some complications and many areas have room for improvement in the 
future. Therefore, further development of this device could potentially result in a fully automated, 
multiplexed assay system that minimizes cost and manual involvement while also increasing reliability 
and reproducibility.  
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Appendices 
Appendix A: Potential Pretotype Brochure 
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Appendix B: R&D Systems Mycoprobe Mycoplasma Detection Assay Kit 
Procedure   
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Appendix C: MyBioSource BSA Detection Assay Procedure
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Appendix D: Syringe Pump Calibration Curve Determination Experiment (Full) 
To perform this experiment, the group used the pre-existing syringe pump assembly consisting 
of a 1ml glass syringe and linear actuator enclosed in a metal assembly. The assembly was connected to 
a programmed Arduino Uno controller board to initiate and terminate movement of the linear actuator. 
The Arduino code was programmed to prompt the user for a position value that the linear actuator 
would then travel to. Open the Arduino software program “PumpAndValve.ino” on the computer and 
enter “0” value for the position of the linear actuator to bring the linear actuator to initial position 
corresponding to zero volume in the syringe. Then, press “x” to confirm and enter the value.  NOTE: 
Press “x” after entering the desired value. After entering the position, enter the desired speed of the 
linear actuator to “150” and enter “x” to run the system. NOTE: Always enter each digit of the desired 
value individually for both position and speed (Example: 150, Enter). Later enter “x” after inputting the 
desired value for both location and speed (Example: 150, Enter, x). The program will ask for an input for 
the speed of the linear actuator only at the start of the program (after inputting the first desired location 
of the position of the linear actuator). The linear actuator will run at the same entered speed (here 150) 
for different input value positions of the linear actuator until the Arduino program is closed and re-run.  
 Measuring the maximum volume of the glass syringe in the syringe pump assembly: In order to do 
so, first tare the mass scale to zero with the doors closed. Place a water filled glass vial (vial A) on the 
scale (capped). Close the scale doors and record the mass. NOTE: Record the mass when the “g” symbol 
appears on the scale. Uncap the vial A and place the tube connected to the glass syringe into the vial A 
to pump water from the vial A into the glass syringe within the syringe pump assembly. Within the same 
Arduino Software Program window input “1000” value for the position of the linear actuator to fill the 
syringe with water from the vial A. NOTE: The tube from the glass syringe is placed into the filled and 
weighed glass vial. After entering each digit of “1000” individually (Example: 1000. Enter) enter “x” to 
run the program (Example: 1000. Enter, x). The pump will start to pull water from the filled vial to the 
glass syringe. Now take another empty vial (vial B) and empty out water from the glass syringe to the 
empty vial by entering “0” for the position of the linear actuator. This will pump out all the water from 
the syringe. Now measure the weight of the vial A with the remaining water using the scale (Ensure to 
cap the vial and close the doors of the scale before measuring). Calculate the amount of water filled in 
the glass syringe= total weight of the filled vial A– weight of the vial A with remaining water. Perform 
the test 3 times and calculate the mean of water filled in the glass syringe. 
 
 Calibration Curve Experiment Maximum Syringe Volume Intake Results 
Total weight of the filled vial (g) Vial weight after filling the 
syringe (g) 
Maximum volume intake of the 
syringe (uL) 
13.4468 12.6602 787 
12.6602 11.8738 786 
11.8738 11.0892 785 
11.0892 10.3002 789 
Mean Volume Intake: 0.7866g=787uL 
 
 Setting up an empty vial to collect the output volume from the Syringe Pump Assembly: In order to 
do so, we first enter “0” (in the Arduino software program) for the position of the linear actuator to 
ensure all the water is out of the system. Press “x” and enter to run the program. Take another filled 
glass vial (vial C). Uncap the water filled vial and place the glass syringe tube into the water filled glass 
vial. Enter “1000” for the position of the linear actuator to fill the glass syringe within the syringe pump 
to its maximum capacity. Press “x” and enter to run the program. Now take an empty glass vial (vial D) 
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and record the mass of the empty vial. NOTE: Ensure to tare the scale before measuring the mass of the 
empty vial. Also close the scale doors while measuring the weight of the vial. Now replace the glass vial C 
with an empty glass vial (vial D). In the same Arduino software program “Enter position of linear 
actuator” on the computer, input random positions of the linear actuator. NOTE: Input random values 
from “0” (Initial position of the linear actuator) to “1000” (Maximum distance traveled by the linear 
actuator within the syringe pump assembly). Collect the pumped water in the vial D. Measure the total 
mass of the vial D. Calculate the mass of the water dispensed at the input random location= total mass 
of the vial D - mass of the empty vial D.  Repeat the previous steps for twelve random positions for the 
linear actuator.  Repeat the previous step two more times for the same 12 positions of the linear 
actuator.   
Experimental Results and Analysis   
Calibration Curve Experiment Iteration 1 Results 
Start Position Input Position Actual End Position Distance Traveled  Volume Output (uL) 
1000 0 0 1000 775 
1000 38 57 943 753 
1000 281 306 694 583 
1000 324 339 661 552 
1000 417 (incorrect) N/A  N/A 486 
1000 500 518 482 418 
1000 622 639 361 318 
1000 635 655 345 385 
1000 773 784 216 218 
1000 815 836 164 168 
1000 873 884 116 123 
1000 950 956 44 66 
 
Calibration Curve Experiment Iteration 2 Results 
Start Position Input Position Actual End Position Distance Traveled  Volume Output (uL) 
1000 0 17 983 772 
1000 38 43 957 772 
1000 281 296 704 583 
1000 324 336 664 562 
1000 450 472 528 460 
1000 500 517 483 320 
1000 622 631 369 332 
1000 635 656 344 312 
1000 773 799 201 210 
1000 815 833 167 167 
1000 873 892 108 224 
1000 950 951 49 63 
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Calibration Curve Experiment Iteration 3 Results 
Start Position Input Position Actual End Position Distance Traveled  Volume Output (uL) 
1000 0 0 1000 793 
1000 38 54 946 763 
1000 281 299 701 580 
1000 324 341 659 (outlier) 101(outlier) 
1000 417 421 579 498 
1000 500 528 472 412 
1000 622 636 364 265 
1000 635 648 352 313 
1000 773 792 208 205 
1000 815 819 181 189 
1000 873 892 108 114 
1000 950 955 45 63 
 
 
Volume vs. Distance Traveled for Iterations 1, 2, and 3 
               Outliers are highlighted in the table above but removed from graph 
 
 
Calibration curve experiment volume output vs distance traveled for iterations 1-3 with outliers 
removed 
 
 
Data Test 1  
(With Outlier) 
Test 2 Test 3  
(With Outlier) 
y=mx+c y = 0.7429x + 56.842 y = 0.7277x + 61.484 y = 0.6918x + 34.281 
y = 0.75x + 51.36
R² = 0.98
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R square R² = 0.9883 R² = 0.9594 R² = 0.75 
 
 
Data Test 1  
(Without Outlier) 
Test 2 Test 3  
(Without Outlier) 
y=mx+c y = 0.7429x + 56.842 y = 0.7277x + 61.484 y = 0.7685x + 35.099 
R square R² = 0.9883 R² = 0.9594 R² = 0.9943 
 
After we removed the outlier from Test 3 the value of m (Slope) in y=mx+c became closer to the 
m (Slope) values obtained from both Tests 1 and 2. Also, after removing the outliers in Test 3, the R 
square values of Test 3 became closer to the R square values obtained in Test 1 and 2. These R square 
values in Test 1,2 and 3 were also closer to approximately 1. The team also thought that possible 
reasons for outliers could be Human error or Instrument error.  
 
Actual Position vs Input Position 
(Outliers are highlighted in the table # above but removed from graph) 
 
  
 
 
ANALYSIS:  
 
Data Test 1  
(With Outlier) 
Test 2 Test 3  
(With Outlier) 
y=mx+c y = 1.04x - 41.928 y = 0.9968x - 13.424 y = 0.997x - 11.944 
R square R² = 0.8745 R² = 0.9995 R² = 0.9993 
 
 
Data Test 1  
(Without Outlier) 
Test 2 Test 3  
(Without Outlier) 
y=mx+c y = 0.9997x + 14.968 y = 0.9968x - 13.424 y = 0.997x - 11.083 
y = 1.04x - 41.928
R² = 0.8745
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R square R² = 0.9995 
 
R² = 0.9995 R² = 0.9993 
 
After removing the outlier from Test 1 the value of m(Slope) in y=mx+c are close to the slope 
values obtained from Test 2 and 3. Also, after removing the outliers, the values of R square for Test 1, 2, 
and 3 are pretty close and are also close to approximately 1. The reasons for the outliers are Human 
error possibly, because the outlier’s actual position wasn’t written down (indication N/A in Test1).  
 
Syringe Pump with Manifold: Dead Volumes Experiment 
 The previous steps with Manifold attached to the syringe pump. NOTE: While filling the 
syringe to its complete capacity, remove the manifold and fill the syringe with similar procedure. 
Connect the manifold right after inputting water. And continue the next steps. 
 
Syringe pump with manifold dead volumes experiment results: Iteration 1 
Desired Output 
Volume(uL) 
Actual Output Volume 
(uL) 
Goal Position Actual Position 
30 0 959 959 
50 49 932 933 
90 99 878 880 
100 118 865 n/a* 
150 164 798 n/a* 
200 198 731 733 
300 274 596 600 
350 263 529 534 
500 455 327 n/a* 
600 543 193 194 
700 562 59 60 
796 741 0 1 
*Due to human error, actual position was not recorded 
 
Syringe pump with manifold dead volumes experiment results: Iteration 2 
Desired Output Volume(ul) Actual Output Volume 
(uL) 
Goal Position Actual Position 
30 0 959 957 
50 45 932 933 
90 48 878 n/a* 
100 108 865 866 
150 122 798 800 
200 134 731 734 
300 67 596 n/a* 
350 234 529 532 
500 722 327 330 
600 595 193 194 
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700 629 59 60 
796 729 0 1 
*Due to human error, actual position was not recorded 
 
Syringe pump with manifold dead volumes experiment results: Iteration 3 
Desired Output Volume(ul) Actual Output Volume 
(ul) 
Desired Position Actual Position 
30 13 959 959 
50 49 932 933 
90 88 878 880 
100 107 865 867 
150 129 798 799 
200 167 731 732 
300 264 596 600 
350 305 529 533 
500 467 327 331 
600 553 193 196 
700 646 59 n/a* 
796 737 0 1 
*Due to human error, the actual position was not recorded  
 
 
Syringe pump with manifold dead volumes experiment goal vs actual output results for iterations 1-3 
 
 
Observations: 
y = 0.9153x - 7.3076
R² = 0.9866
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Data Test 1  Test 2  Test 3  
(With Outlier) 
y=mx+c y = 0.8686x + 9.0011 y = 1.0158x - 41.19 y = 0.9287x - 5.4455 
R square R² = 0.983 R² = 0.8722 R² = 0.9982 
 
Data Test 1  Test 2 Test 3  
(Without Outlier) 
y=mx+c y = 0.8686x + 9.0011 y = 0.9483x - 26.35 y = 0.9287x - 5.4455 
R square R² = 0.983 R² = 0.9838 R² = 0.9982 
 
ANALYSIS: 
R²: After removing the outlier the R² value for Test 2 changed from 0.8722 to 0.9838. It can be observed 
that the values of R² are very close to 1 after removing the outliers in Test 2. Also, the combined tests 
have R² = 0.9866.  
SLOPE: The graphs obtained are pretty linear and the slope values for Test 1 and 3 are relatively close. 
After removing the outlier from Test 2, the slope values for Test 2 are relatively close to the test values 
of Test 1 and Test 3. The combined tests have slope (m)= 0.9153. 
OUTLIERS: There exist 2 significant outliers in Test 2. The possible reasons for outlier are either human 
error or instrument error. 
 
            
 Observations: 
Data Test 1  Test 2 Test 3  
(With Outlier) 
y=mx+c y = 0.7346x - 12.517 y = 0.8025x + 30.689 y = 1.0221x - 15.657 
R square R² = 0.4009 R² = 0.5578 R² = 0.998 
 
Data Test 1  Test 2 Test 3  
(Without Outlier) 
y=mx+c y = 1.0002x + 1.7836 y = 0.9994x + 1.5498 y = 0.9982x + 3.2175 
R square R² = 1 R² = 1 R² = 1 
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OUTLIERS: There exist 5 significant outliers in Test 1, 2, and 3. The possible reasons for outlier was that 
the Actual Position wasn’t recorded (HUMAN ERROR). 
R²: After removing the outliers, the R² value for Test 1, Test 2 and Test 3 = 1.  
SLOPE: After removing the outliers, the slope is pretty linear and the values for the Test 1,2 and 3 are 
close. 
 
Comparison of with and without manifold volume outputs 
 
Volume output comparison between system with and without manifold 
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Appendix E: Syringe Pump with Manifold: Dead Volumes Experiment (Full) 
The purpose of this experiment was to determine volume lost in the valve manifold 
 
Steps: In order to perform this test, we took the already existing Syringe pump assembly consisting of 
1ml glass syringe and linear actuator enclosed using metal assembly and connected it to the Solenoid 
manifold using a 1/32 inch tube. We connected it to the Arduino and the power supply. We also 
connected a 1/32 inch diameter tube to the manifold assembly to pump water out. 
 
Setting up Arduino Software Program: Open the Arduino software program “PumpAndValve.ino” on the 
computer and enter “0” value to move the syringe to initial position corresponding “0” volume in the 
syringe. Enter “x” in the Arduino software to confirm. After entering the volume, enter the desired 
speed of the linear actuator to “150” and enter “x” to run the system. NOTE: Always enter each digit of 
the desired value individually for both volume and speed. (Example: 150, Enter). Always enter “x” after 
inputting the desired value for both volume and speed. (Example: 150, Enter, x). The program will ask 
for an input for the speed of the linear actuator only at the start of the program (after inputting the first 
desired volume). The linear actuator will run at the same entered speed (here 150) for different values 
of volumes until the Arduino program is closed and re-run. 
 
Setting up an empty vial to collect the output volume from the Syringe Pump Assembly (Without 
Manifold): Take a filled glass vial (vial A). Uncap the water filled vial A and place the glass syringe tube 
into the water filled glass vial. Enter “796” in the same Arduino program: “B: Enter volume” to fill the 
syringe at its maximum capacity. Enter “x” to run. Now take an empty glass vial (vial B) and record the 
mass of the empty vial. NOTE: Ensure to tare the scale before measuring the mass of the empty vial 
(capped). Also close the scale doors while measuring the weight of the vial. Now replace the glass vial A 
with an empty glass vial (vial B). (Place the syringe tube into vial B). Subtract a desired volume from 796 
(maximum capacity of the syringe). (Example: 50 ul = 796-50=746). Enter the volume value (calculated) 
to be dispensed in the glass vial B. Enter “x” to run the program. NOTE: The test will be performed at the 
volumes in the following tables: 
 
ASSAY VOLUME 
 (ml) 
BSA/Mycoplasma 0.05ml 
BSA 0.09ml 
BSA  0.10ml 
Mycoplasma 0.15ml 
Mycoplasma 0.20ml 
BSA/Mycoplasma 0.30ml 
BSA 0.35ml 
BSA 0.60ml 
 
 
Record the total mass of the vial B with the dispensed water. Calculate the mass of the output water = 
total mass of the water filled vial B - mass of the empty vial B. Repeat the previous steps for all the 
different volumes in the tables above. Repeat the previous step two more times for the same volumes.   
 
(Without Manifold) Re-run the test two times and record the data in the following table: 
 
                  MINIMUM 
                      (mL) 
                  MAXIMUM 
                       (mL) 
                       0.03                      0.8 
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DESIRED  
OUTPUT VOLUME(uL) 
                ACTUAL 
OUTPUT VOLUME (uL) 
30 23 
50 52 
90 100 
100 110 
150 169 
200 215 
300 324 
350 376 
500 515 
600 620 
700 716 
796 760 
 
 
Re-run the test the second time and record the data in the following table: 
 
DESIRED  
OUTPUT VOLUME(uL) 
                ACTUAL 
OUTPUT VOLUME (uL) 
30 26 
50 52 
90 100 
100 113 
150 166 
200 220 
300 325 
350 369 
500 530 
600 625 
700 723 
796 763 
 
 
Steps (With Manifold): Repeat the previous steps with Manifold attached to the syringe pump. NOTE: 
While filling the syringe to its complete capacity, remove the manifold and fill the syringe with similar 
procedure. Connect the manifold right after inputting water. And continue the next steps. 
 
Collecting Data (With Manifold) 
 
DESIRED OUTPUT 
VOLUME(uL) 
ACTUAL OUTPUT 
VOLUME (uL) 
DESIRED  
POSITION 
ACTUAL 
 POSITION 
30 0 959 959 
50 49 932 933 
90 99 878 880 
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100 118 865 n/a 
150 164 798 n/a 
200 198 731 733 
300 274 596 600 
350 263 529 534 
500 455 327 n/a 
600 543 193 194 
700 562 59 60 
796 741 0 1 
 
Repeat step two more times. 
 
DESIRED OUTPUT 
VOLUME(uL) 
ACTUAL OUTPUT 
VOLUME (uL) 
DESIRED  
POSITION 
ACTUAL 
 POSITION 
30 0 959 957 
50 45 932 933 
90 48 878 n/a 
100 108 865 866 
150 122 798 800 
200 134 731 734 
300 67 596 n/a 
350 234 529 532 
500 722 327 330 
600 595 193 194 
700 629 59 60 
796 729 0 1 
 
 
 
DESIRED OUTPUT 
VOLUME(uL) 
ACTUAL OUTPUT 
VOLUME (uL) 
DESIRED  
POSITION 
ACTUAL 
 POSITION 
30 13 959 959 
50 49 932 933 
90 88 878 880 
100 107 865 867 
150 129 798 799 
200 167 731 732 
300 264 596 600 
350 305 529 533 
500 467 327 331 
600 553 193 196 
700 646 59 n/a 
796 737 0 1 
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ACTUAL VS GOAL VOLUME OUT- WITHOUT MANIFOLD Test 1 and 2 
 
 
Observations: 
Data Test 1  Test 2 
y=mx+c y = 0.9863x + 13.911 y = 0.9943x + 14.004 
R square R² = 0.996 R² = 0.9958 
 
R²: It can be observed that the values of R² are very close to 1. SLOPE: The graphs obtained are pretty 
linear and the slope values for Test 1 and 2 are close. OUTLIERS: The graphs don’t have any significant 
outliers. 
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ACTUAL VS GOAL VOLUME OUT- WITH MANIFOLD Test 1, 2 and 3 
WITH OUTLIERS               WITHOUT OUTLIERS 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
        
 
 
 
Combined Data for Test 1, 2 and 3 
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y = 0.9153x - 7.3076
R² = 0.9866
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Observations:    
 
Data Test 1  Test 2  Test 3  
(With Outlier) 
y=mx+c y = 0.8686x + 9.0011 y = 1.0158x - 41.19 y = 0.9287x - 5.4455 
R square R² = 0.983 R² = 0.8722 R² = 0.9982 
 
Data Test 1  Test 2 Test 3  
(Without Outlier) 
y=mx+c y = 0.8686x + 9.0011 y = 0.9483x - 26.35 y = 0.9287x - 5.4455 
R square R² = 0.983 R² = 0.9838 R² = 0.9982 
 
ANALYSIS: 
 
R²: After removing the outlier the R² value for Test 2 changed from 0.8722 to 0.9838. It can be observed 
that the values of R² are very close to 1 after removing the outliers in Test 2. Also, the combined tests 
have R² = 0.9866.  
SLOPE: The graphs obtained are pretty linear and the slope values for Test 1 and 3 are relatively close. 
After removing the outlier from Test 2, the slope values for Test 2 are relatively close to the test values 
of Test 1 and Test 3. The combined tests have slope (m)= 0.9153. 
OUTLIERS: There exist 2 significant outliers in Test 2. The possible reasons for outlier are either human 
error or instrument error. 
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ACTUAL VS GOAL POSITION- WITH MANIFOLD Test 1, 2 and 3 
WITH OUTLIERS                                                               WITH OUTLIERS 
NOTE: Removed 2 outliers from the previous volume analysis for Test 2 
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Observations: 
 
Data Test 1  Test 2 Test 3  
(With Outlier) 
y=mx+c y = 0.7346x - 12.517 y = 0.8025x + 30.689 y = 1.0221x - 15.657 
R square R² = 0.4009 R² = 0.5578 R² = 0.998 
 
Data Test 1  Test 2 Test 3  
(Without Outlier) 
y=mx+c y = 1.0002x + 1.7836 y = 0.9994x + 1.5498 y = 0.9982x + 3.2175 
R square R² = 1 R² = 1 R² = 1 
 
OUTLIERS: There exist 5 significant outliers in Test 1, 2, and 3. The possible reasons for outlier was that 
the Actual Position wasn’t recorded (HUMAN ERROR). 
R²: After removing the outliers, the R² value for Test 1, Test 2 and Test 3 = 1.  
SLOPE: After removing the outliers, the slope is pretty linear and the values for the Test 1,2 and 3 are 
close. 
 
Test3: Air Pump Integration 
 
The purpose of this experiment was to determine if using an air pump helped lessen dead volumes by 
flushing the remaining dead volumes left behind.  
 
Steps: In order to perform this test, we took the already existing Syringe pump assembly consisting of 
1ml glass syringe and linear actuator enclosed using metal assembly and connected it to the Solenoid 
manifold using a 1/32 inch tube. We connected it to the Arduino and the power supply. We also 
connected a 1/32 inch diameter tube to the manifold assembly to pump water out. We also connected 
the air pump to manifold and syringe pump.  
 
Setting up an empty vial to collect the output volume from the Manifold: Take a filled glass vial (vial A). 
Uncap the water filled vial A and place the glass syringe tube into the water filled glass vial. Enter “799” 
in the same Arduino program: “B: Enter volume” to fill the syringe at its maximum capacity. Enter “x” to 
run. Now take an empty glass vial (vial B) and record the mass of the empty vial.  
NOTE: Ensure to tare the scale before measuring the mass of the empty vial (capped). Also close the 
scale doors while measuring the weight of the vial. Connect the manifold to the syringe pump tube.  
NOTE: Fill the syringe pump at its full capacity directly using syringe pump tube instead of connecting it 
to the manifold. Now replace the glass vial A with an empty glass vial (vial B). (Place the manifold tube 
into vial B). Subtract a desired volume from 799 (maximum capacity of the syringe). (Example: 50 ul = 
799-50=749). Enter the volume value (calculated) to be dispensed in the glass vial B. Enter “x” to run the 
program. NOTE: The test will be performed at the volumes in the following tables: 
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ASSAY VOLUME 
 (ml) 
BSA/Mycoplasma 0.05ml 
BSA 0.09ml 
 BSA 0.10ml 
Mycoplasma 0.15ml 
Mycoplasma 0.20ml 
BSA/Mycoplasma 0.30ml 
BSA 0.35ml 
BSA 0.60ml 
 
Enter “y” in the Arduino code to start the air pump. Stop the air pump by entering “s” in the Arduino 
code. Stop after 1 second. Record the total mass of the vial B with the dispensed water. Calculate the 
mass of the output water = total mass of the water filled vial B - mass of the empty vial B. Repeat the 
previous steps for all the different volumes in the tables above. Repeat the previous step two more 
times for the same volumes.   
 
Collecting Data  
 
DESIRED OUTPUT 
VOLUME(uL) 
ACTUAL OUTPUT 
VOLUME (uL) 
30 15.1 
50 13.1 
90 25.6 
100 63.3 
150 110.8 
200 179.8 
300 293.4 
450 (Instead of 350) 398.6 
500 393.7 
600 576.6 
700 670.9 
799 500.3 
 
DESIRED OUTPUT 
VOLUME(uL) 
ACTUAL OUTPUT 
VOLUME (uL) 
30 16.1 
50 31.8 
90 77.1 
100 70.8 
150 144.4 
200 182.7 
                  MINIMUM 
                      (mL) 
                  MAXIMUM 
                       (mL) 
                       0.03 0.8 
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y = 0.8351x - 6.1035
R² = 0.9215
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300 265.7 
350 343.8 
500 494 
600 599.6 
700 692.3 
799 718.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Goal Output VS Actual Output 
WITH OUTLIERS IN TEST                                       WITHOUT OUTLIERS IN TEST 1 
 
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
             
DESIRED OUTPUT 
VOLUME(uL) 
ACTUAL OUTPUT 
VOLUME (uL) 
30 -1.8 
50 10.9 
90 69.6 
100 68.6 
150 130.7 
200 146.9 
300 289 
350 330.5 
500 489.7 
600 581.6 
700 672.6 
799 703.6 
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y = 0.9727x - 22.607
R² = 0.9927
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Data Test 1  
(With Outlier) 
Test 2 Test 3  
 
y=mx+c y = 0.8351x - 6.1035 y = 0.9743x - 11.069 y = 0.9727x - 22.607 
R square R² = 0.9215 R² = 0.9938 R² = 0.9927 
 
Data Test 1  
(Without Outlier) 
Test 2 Test 3  
 
y=mx+c y = 1.0333x - 30.847 y = 0.9743x - 11.069 y = 0.9727x - 22.607 
R square R² = 0.9861 R² = 0.9938 R² = 0.9927 
 
 
Observations: 
 
OUTLIERS: There exist 2 significant outliers in Test 1. The possible reasons for outlier are human error or 
instrument error. 
R²: After removing the outlier the R² value for Test 1 changed from 0.9215 to 0.9861. It can be observed 
that the values of R² are very close to 1 after removing the outliers in Test 2.  
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SLOPE: The graphs obtained are pretty linear and the slope values for Test 2 and 3 are relatively close. 
After removing the outlier from Test 1, the slope value for Test 1 is relatively close to the test values of 
Test 2 and Test 3. 
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Appendix F: Syringe Pump with Manifold: Intake Inaccuracies Experiment 
(Full) 
 In order to perform this test, we took the already existing Syringe pump assembly consisting of 
1ml glass syringe and linear actuator enclosed using metal assembly and connected it to the Solenoid 
manifold using a 1/32 inch tube. We connected it to the Arduino and the power supply. We also 
connected a 1/32 inch diameter tube to the manifold assembly to intake water.  
 Open the Arduino software program “PumpAndValve.ino” on the computer and enter “0” value 
to move the syringe to initial position corresponding “0” volume in the syringe. Enter “x” to confirm. 
After entering the position, enter the desired speed of the linear actuator to “150” and enter “x” to run 
the system. NOTE: Always enter each digit of the desired value individually for both volume and speed. 
(Example: 150). Always enter “x” after inputting the desired value for both volume and speed. (Example: 
1, Enter, 5, Enter, 0, Enter, x). The program will ask for an input for the speed of the linear actuator only 
at the start of the program (after inputting the first desired volume). The linear actuator will run at the 
same entered speed (here 150) for different values of volumes until the Arduino program is closed and 
re-run. 
Start with full glass vial of water. Weigh on tared scale to get total mass. NOTE: Ensure to tare 
the scale before measuring the mass of the vial (capped). Also close the scale doors while measuring the 
weight of the vial. Start syringe at volume 0. Put tubing into glass vial and input desired volume into 
Arduino interface.  Begin program so pump fills syringe. 
When syringe is full to desired volume position, weigh the vial again to see how much water is actually 
taken into the syringe  
Input volume 0 into the Arduino software to empty out all contents of the syringe into the same 
vial. Weigh again to see how much volume was dispensed. We chose a range of volumes between 0 and 
700 to ensure that the pump is consistent. We also ensured appropriate values to reflect the values we’ll 
need for the assays. 
 
 
Goal Intake (uL) Actual Intake (uL) 
Iteration 1 
Actual Intake (uL) 
Iteration 2 
Actual Intake (uL) 
Iteration 3 
30 1 5 3 
50 5 1 1 
90 21 20 19 
100 27 38 26 
150 78 72 69 
200 114 115 111 
300 200 203 199 
350 247 402 246 
500 401 400 403 
600 510 528 509 
799 773 765 767 
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Results of system intake experiment: goal intake vs. actual intake 
 
 
 
Results of system intake experiment: Change in intake volume vs. goal volume intake 
We obtained a pretty linear relationship for Actual Intake vs. Goal Intake with y= 1.03x-89.42. 
Also the value of R square equals 0.99, close to 1. After obtaining another graph representing Difference 
in Volume vs. Goal Volume Intake, we observed that a constant volume difference wasn’t observed. 
Also, after looking at the graph, constant trend of loss of volume wasn’t observed.  
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Appendix G: Syringe Pump with Manifold and Air Pump: Output Volume Loss 
Experiment (Full) 
In order to perform this test, we took the already existing Syringe pump assembly consisting of 
1ml glass syringe and linear actuator enclosed using metal assembly and connected it to the Solenoid 
manifold using a 1/32 inch tube. We connected it to the Arduino and the power supply. We also 
connected a 1/32 inch diameter tube to the manifold assembly to pump water out. We also connected 
the air pump to manifold and syringe pump.  
 Take a filled glass vial (vial A). Uncap the water filled vial and place the glass syringe tube into the 
water filled glass vial. Enter “799” in the same Arduino program: “PumpAndValve.ino” to fill the syringe 
at its maximum capacity. Enter “x” to run. Now take an empty glass vial (vial B) and record the mass of 
the empty vial. NOTE: Ensure to tare the scale before measuring the mass of the empty vial (capped). 
Also close the scale doors while measuring the weight of the vial. Connect the manifold to the syringe 
pump tube. NOTE: Fill the syringe pump at its full capacity directly using syringe pump tube instead of 
connecting it to the manifold. 
 Now replace the glass vial A with an empty glass vial (vial B). (Place the manifold tube into vial B). 
Subtract a desired volume from 799 (maximum capacity of the syringe). (Example: 50 µl = 799-50=749). 
Enter the volume value (calculated) to be dispensed in the glass vial B. Enter “x” to run the program. 
NOTE: The test will be performed at the volumes in the following tables: 
 
Assay Volume (uL) 
Minimum 30 
BSA/Mycoplasma 50 
BSA 90 
 BSA 100 
Mycoplasma 150 
Mycoplasma 200 
BSA/Mycoplasma 300 
BSA 350 
BSA 600 
Maximum 800 
 
 Enter “y” in the Arduino code to start the air pump. Stop the air pump by entering “s” in the 
Arduino code. Stop after 1 second. Record the total mass of the vial B with the dispensed water. 
Calculate the mass of the output water = total mass of the water filled vial B - mass of the empty vial B. 
Repeat the previous steps for all the different volumes in the tables above. Repeat the previous step two 
more times for the same volumes.   
 
Experimental Results and Analysis  
 
Desired Output 
Volume (uL) 
Actual Output Volume: 
Iteration 1  (uL) 
Actual Output Volume: 
Iteration 2 (uL) 
Actual Output Volume: 
Iteration 3 (uL) 
30 15.1 16.1 -1.8 
50 13.1 31.8 10.9 
90 25.6 77.1 69.6 
100 63.3 70.8 68.6 
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150 110.8 144.4 130.7 
200 179.8 182.7 146.9 
300 293.4 265.7 289 
350 398.6*  343.8 330.5 
500 393.7 494 489.7 
600 576.6 599.6 581.6 
700 670.9 692.3 672.6 
799 500.3 718.6 703.6 
*In Iteration 1, value measured at 450µL due to human error. 
 
Goal Output VS Actual Output 
(Outliers highlighted in table # but removed from graph) 
 
 
Data Test 1  
(With Outlier) 
Test 2 Test 3  
 
y=mx+c y = 0.8351x - 6.1035 y = 0.9743x - 11.069 y = 0.9727x - 22.607 
R square R² = 0.9215 R² = 0.9938 R² = 0.9927 
 
Data Test 1  
(Without Outlier) 
Test 2 Test 3  
 
y=mx+c y = 1.0333x - 30.847 y = 0.9743x - 11.069 y = 0.9727x - 22.607 
R square R² = 0.9861 R² = 0.9938 R² = 0.9927 
 
 
Observations: 
 
OUTLIERS: There exist 2 significant outliers in Test 1. The possible reasons for outlier are human error or 
instrument error. 
R²: After removing the outlier the R² value for Test 1 changed from 0.9215 to 0.9861. It can be observed 
that the values of R² are very close to 1 after removing the outliers in Test 2.  
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SLOPE: The graphs obtained are pretty linear and the slope values for Test 2 and 3 are relatively close. 
After removing the outlier from Test 1, the slope value for Test 1 is relatively close to the test values of 
Test 2 and Test 3. 
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Appendix H: BSA Water Trial Experiment: Full 
Purpose: Determine if proof-of-concept device has the accuracy and precision to dispense volumes 
required for BSA assay. The trial was run with water rather than reagents. 
 
Open the Arduino software program “PumpAndValve.ino” on the computer and enter “0” value to move 
the syringe to initial position corresponding “0” volume in the syringe. Enter “x” in the Arduino software 
to confirm. After entering the volume, enter the desired speed of the linear actuator to “250” and enter 
“x” to run the system. Enter the goal intake volume into the Arduino code; the goal volumes are listed in 
the following table: NOTE: 50uL input buffer is used because of variability. 
NOTE: Air Pump after pumping each reagent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enter the volumes to intake in the Arduino code as listed in the table above, and begin to fill the syringe 
from the manifold input/output valve ports (which manifold input ports are designated for which 
reagent volumes). Now dispense the volume in the same input/output valve port from syringe pump 
into each well using manual tubing control. Calculate the actual output volumes using mass 
 difference calculations. Repeat each run with 6 wells at each volume three times.  
 
The intake and output w/ buffer volume was calculated as listed in the following table: 
Intake w/ buffer 
volume 
100uL   150uL 350uL 140uL 
Average Intake 
Volume (uL) 
36 81 270 72 
Average Intake 
Difference (uL) 
62 69 80 57 
Overall CV of Intake 
Volume (%) 
70 10 2 8 
 
 
 
 
Reagent Volume 
Detection Reagent A  50uL 
Detection Reagent B 100uL 
Wash Buffer  300uL 
Substrate Solution  90uL 
Stop Solution  50uL 
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Output w/ buffer 
Volume  
100uL  150uL 350uL 140uL 
Average Ouput 
Volume (uL) 
18 54 209 52 
Average Output 
Volume Lost (uL) 
15 15 11 8 
Overall CV of 
Output Volume (%) 
48 24 6 2 
 
 
Average Intake Difference (uL) 70uL 
Average Output Losst (uL) 15uL 
 
 
The following volumes were calculated to ensure requested volumes achieve desired output volume:  
 
Goal Output Volume Actual Arduino Input (uL) Rounded Arduino Input (uL) 
50uL 127 130 
90uL 155 170 
100uL 174 180 
300uL 391 380 
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Appendix I: System BSA Assay Experiment Data 
 
 
 
Log of Concentration OD: Iteration 1 OD: Iteration 2 OD: Baseline  
4.477 0.44 0.599 0.15 
4 0.964 0.622 0.23 
3.523 0.906 0.834 0.266 
3.046 3.1 1.64 0.5 
2.569 2.99 2.45 1.06 
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Appendix J: System Mycoplasma Experiment Data 
 
 
 Mycoplasma Baseline Assay System Mycoplasma Assay  
Positive Control Readings at 490nm 2.05 
       2.02 
2.16 
4.49 
4.57 
4.34 
Negative Control Readings at 490nm 0.161 
0.1 
0.113 
0.354 
0.334 
0.516 
Positive at 600nm  0.874 
0.948 
0.916 
1.48 
1.48 
1.38 
Negative at 600nm 0.0822 
0.0575 
0.0736 
0.116 
0.113 
0.168 
Difference Positive 1.123 
1.109 
1.191 
3.01 
3.09 
2.96 
Difference Negative 0.0252 
-0.011 
-0.141 
0.238 
0.221 
0.348 
 
 
